

1 UNITED STATES PATENT AND TRADEMARK OFFICE

2
3 BEFORE THE PATENT TRIAL AND APPEAL BOARD

4
5 IMPERATIVE CARE, INC.,
6 Petitioner,
7 v.

8 INARI MEDICAL, INC.,
9 Patent Owner.

10 Case No. IPR2025-01021
11 U.S. Patent No. 11,969,333

12 Case No. IPR2025-01025
13 U.S. Patent No. 11,974,910

14 Case No. IPR2025-01264
15 U.S. Patent No. 12,016,580

16 TESTIMONY OF

17 TROY LANE THORNTON

18 WEDNESDAY, JULY 1, 2026

19 San Francisco, California

20 9:16 a.m. PDT

21 to

22 1:11 p.m. PDT

23 Stenographically Reported by:
24 Burgundy B. Ryan, RPR,
25 CSR No. 11373
Job No. 638725
Pages 1-84

A P P E A R A N C E S

ON BEHALF OF THE PETITIONER:

KNOBBE MARTENS OLSON & BEAR LLP
By: JOSHUA STOWELL, Esquire
2040 Main Street
14th Floor
Irvine, California 92614
949.760.0404
joshua.stowell@knobbe.com

ON BEHALF OF THE PATENT OWNER:

ASHURST PERKINS COIE, LLP
By: JOSEPH HAMILTON, Esquire
1888 Century Park East
Suite 1700
Los Angeles, California 90067
310.788.9900
joseph.hamilton@ashurstperkins.com

ALSO PRESENT:

Philip Astor, Videographer
Planet Depos

DEPOSITION SUPPORT INDEX

QUESTIONS INSTRUCTED NOT TO ANSWER:

PAGE LINE

(None)

REQUEST FOR PRODUCTION OF DOCUMENTS

PAGE LINE

(None)

STIPULATIONS

PAGE LINE

(None)

QUESTIONS MARKED

PAGE LINE

(None)

REPORTER'S NOTE:

QUOTATION MARKS ARE USED FOR CLARITY AND DO NOT

NECESSARILY REFLECT A DIRECT QUOTE.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

I N D E X		
		PAGE
EXAMINATION BY MR. HAMILTON.....		6
--o0o--		
E X H I B I T S		
EXHIBIT	DESCRIPTION	PAGE
(The following previously-marked exhibits were		
discussed: 1020, 1038, 1039, 1067 (IPR2025-01264),		
1067 (IPR2025-01025), 1067 (IPR2025-01021), 1068,		
1075, 1078, and 1079.)		
--o0o--		

1 BE IT REMEMBERED that, pursuant to Notice
2 of Taking Deposition, and on Wednesday, July 1,
3 2026, commencing at 9:16 a.m. PDT thereof, at Knobbe
4 Martens Olson & Bear, 333 Bush Street, San
5 Francisco, California, before me, Burgundy B. Ryan,
6 a Certified Shorthand Reporter in and for the State
7 of California, personally appeared

8 TROY LANE THORNTON,
9 a witness called on behalf of PATENT OWNER, and who, 08:48:26
10 having been first duly sworn by me to testify to the 08:48:26
11 truth, was examined and testified as follows: 08:48:26

12 THE VIDEOGRAPHER: Here begins Media No. 1 09:15:51
13 in the videotaped deposition of Troy Lane Thornton 09:15:53
14 in the matter of Imperative Care, Inc. versus Inari 09:15:56
15 Medical, Inc., in the United States Patent and 09:16:00
16 Trademark Office before the Patent Trial and Appeal 09:16:02
17 Board, case numbers IPR2025-01021, 01025, and 01264. 09:16:05

18 Today's date is July 1st, 2026. 09:16:18

19 The time on the video monitor is 9:16 09:16:22
20 Pacific. 09:16:25

21 The videographer today is Philip Astor 09:16:26
22 representing Planet Depos headquartered at 451 09:16:28
23 Hungerford Drive, Suite 400, Rockville, Maryland 09:16:32
24 20850. 09:16:36

25 This video deposition is taking place at 09:16:38

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

6

1	333 Bush Street, 21st Floor, San Francisco,	09:16:40
2	California.	09:16:44
3	Would Counsel please voice-identify	09:16:45
4	themselves and state whom they represent?	09:16:48
5	MR. HAMILTON: This is Joseph Hamilton from	09:16:49
6	Perkins Coie for Patent Owner.	09:16:52
7	MR. STOWELL: Joshua Stowell of Knobbe	09:16:53
8	Martens on behalf of the Petitioner Imperative Care	09:16:56
9	and the witness.	09:16:59
10	THE VIDEOGRAPHER: The court reporter today	09:17:00
11	is Burgundy Brooke Ryan representing Planet Depos.	09:17:01
12	The witness will now be sworn.	09:17:05
13	COURT REPORTER: Good morning everyone. My	09:17:21
14	name is Burgundy Brooke Ryan, California CSR License	09:17:21
15	No. 11373.	09:17:21
16	(Whereupon, the witness was sworn.)	09:17:22
17	COURT REPORTER: Thank you very much.	09:17:22
18	Counsel, you may proceed.	09:17:22
19	TROY LANE THORNTON,	09:17:22
20	having been first duly sworn to tell the whole	09:17:22
21	truth, testified as follows:	09:17:22
22	EXAMINATION	09:17:22
23	By MR. HAMILTON:	09:17:24
24	Q. Good morning, Mr. Thornton. Welcome back.	09:17:24
25	Do you understand you're under oath?	09:17:27

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01264

1	A. Yes.	09:17:29
2	Q. Are you on any medications that might	09:17:32
3	prevent your full complete and truthful testimony	09:17:35
4	today?	09:17:38
5	A. No.	09:17:39
6	Q. Is there any reason you can't give your	09:17:40
7	full, complete, and truthful testimony here today?	09:17:42
8	A. No.	09:17:45
9	Q. So we've had several depositions in these	09:17:49
10	matters.	09:17:52
11	Do you understand what patents are at	09:17:53
12	issue -- at issue in the depositions here today? In	09:17:54
13	the matters here today? Excuse me.	09:17:57
14	A. I believe so.	09:18:00
15	Q. Would that be the '333 patent, the '580	09:18:02
16	patent, and the '910 patent?	09:18:06
17	A. Yes.	09:18:08
18	Q. Do you understand which patents I'm	09:18:09
19	referring to when I refer to the '333, '580, and	09:18:10
20	'910 patents?	09:18:15
21	A. Yes.	09:18:16
22	Q. I'm going to hand you three documents.	09:18:52
23	Do you recognize these three documents?	09:19:30
24	A. Yes.	09:19:34
25	Q. What are these documents?	09:19:36

1 A. This is my supplemental declaration in
2 support of Petitioner's reply regarding patent
3 number 11,969,333, the second one is the same but
4 relates to a different patent, 12,016,580, and the
5 third one relates to patent number 11,974,910.

6 Q. If you look, each of the documents is
7 marked with an exhibit number at the bottom.

8 Do you see that?

9 A. Yes.

10 Q. And the exhibit number for each one is
11 1067.

12 Do you see that?

13 A. Yes.

14 Q. So to avoid confusion, I'm going to refer
15 to these three declarations as the '580
16 declaration, the '333 declaration -- excuse me. Let
17 me -- let me clarify that.

18 So for each of these matters, this -- this
19 is the second declaration you've submitted in the
20 matter; is that correct?

21 A. Yes.

22 Q. So when I refer to these three
23 declarations, I'm going to refer to them as the '580
24 supplemental declaration, the '333 supplemental
25 declaration, and the '910 supplemental declaration.

1	And if I do that, will you understand which	09:20:58
2	declaration I'm referring to?	09:21:00
3	A. Yes.	09:21:03
4	Q. If at any point there is any confusion and	09:21:03
5	you don't know what document I'm referring to,	09:21:06
6	please feel free to -- to ask. If you don't, we're	09:21:09
7	going to assume you understand which document we're	09:21:11
8	looking at. Is that fair?	09:21:14
9	A. Yes.	09:21:16
10	Q. If you could take a look at the '910	09:21:26
11	declaration.	09:21:30
12	A. Supplemental?	09:21:33
13	Q. Supplemental. Thank you.	09:21:36
14	And if you could turn to page 2, paragraph	09:21:44
15	7. Do you see in paragraph 7 in the first sentence	09:21:48
16	they quote for your opinion for -- the	09:22:22
17	qualifications for a person of ordinary skill in the	09:22:27
18	art.	09:22:30
19	A. Yes.	09:22:31
20	Q. And in the art you're referring to the --	09:22:33
21	the technical field of the '333, '910, or '580	09:22:35
22	patent; is that right?	09:22:40
23	A. Yes.	09:22:43
24	Q. Are you aware of any differences between	09:22:44
25	the technical field of the '333, '910, and '580	09:22:46

1 patents?

09:22:49

2 A. I believe two of them use the exact same
3 specification. The third one, the '580, I believe
4 has a slightly different specification. But I would
5 have to look at the details for each one to see
6 if -- if that '580 is significantly different in its
7 scope.

09:22:57

09:23:01

09:23:05

09:23:10

09:23:14

09:23:17

8 Q. So as you sit here today, are you aware of
9 any difference in the technical field between the
10 three patents the '333, '910, and '580 patents?

09:23:24

09:23:26

09:23:28

11 A. I would have to look at the '580 patent
12 to confirm my thoughts on that.

09:23:37

09:23:40

13 Q. Have you proposed the same definition for a
14 person of ordinary skill in the art in the three --
15 in your three declarations?

09:23:44

09:23:47

09:23:50

16 MR. STOWELL: Objection. Vague.

09:23:55

17 THE WITNESS: It's the same -- it's the
18 same definition in all three of these supplemental
19 declarations.

09:24:21

09:24:33

09:24:36

20 By MR. HAMILTON:

09:24:57

21 Q. If you look at the -- your proposed
22 definition in paragraph 7 of the '910 supplemental
23 declaration, do you see where it says, "two to four
24 years of catheter design experience?"

09:24:57

09:25:00

09:25:07

09:25:14

25 A. Yes.

09:25:17

1 Q. Would an individual meeting the other 09:25:23
2 requirements of your definition and having two to 09:25:28
3 four years of any catheter design experience qualify 09:25:31
4 as a person of ordinary skill in the art, in your 09:25:35
5 opinion? 09:25:37

6 MR. STOWELL: Objection. Vague. 09:25:38

7 THE WITNESS: Well there are a wide range 09:25:56
8 of catheters that engineers may have worked on, but 09:25:57
9 I think having two to four years of general catheter 09:26:03
10 experience would be sufficient to consider that 09:26:07
11 person as a person of ordinary skill in the art. 09:26:15

12 By MR. HAMILTON: 09:26:17

13 Q. And when you say "catheter design 09:26:17
14 experience," you mean designing any catheter; is 09:26:20
15 that correct? 09:26:25

16 A. I didn't specify any types of catheters, I 09:26:26
17 just said catheter design experience -- 09:26:28

18 Q. So is there any limit on the -- excuse me, 09:26:30
19 please. 09:26:32

20 A. Experience is what I meant to say. 09:26:33

21 Q. Is there -- is there any further 09:26:35
22 qualification for catheter design experience that 09:26:37
23 you would like to add? 09:26:39

24 A. No. 09:26:41

25 Q. So it's your opinion that a person of 09:26:43

1 ordinary skill in the art that meets the other 09:26:45
2 requirements in your definition and has two to four 09:26:48
3 years of catheter design experience, regardless of 09:26:50
4 the type of catheter, what that catheter is used 09:26:54
5 for, qualifies as a person of ordinary skill in the 09:26:57
6 art; is that correct? 09:26:59

7 A. What I said was two to four years of 09:27:04
8 catheter design experience and I didn't limit it to 09:27:07
9 any certain types of catheters, correct. 09:27:10

10 Q. So when you say "two to four years of 09:27:13
11 catheter design experience," you mean any catheter 09:27:16
12 design experience regardless of the type of catheter 09:27:19
13 or what the catheter is used for; is that correct? 09:27:21

14 A. I didn't provide any more limitations 09:27:24
15 beyond catheter design experience of two to four 09:27:27
16 years. 09:27:30

17 Q. And are there any other limitations besides 09:27:31
18 catheter design experience of two to four years in 09:27:35
19 your definition of a person of ordinary skill in the 09:27:39
20 art? 09:27:41

21 A. It's what I said -- 09:27:42

22 Q. So that's a no? 09:27:44

23 A. -- in paragraph 7. 09:27:45

24 Q. So is that a no? 09:27:46

25 A. I didn't put any additional limits or 09:27:52

1 considerations or requirements as to the type of
2 catheter design experience in my definition.

3 Q. In the context of the field of the patents
4 at issue here, what does thrombectomy mean?

5 MR. STOWELL: Objection. Lack of
6 foundation.

7 THE WITNESS: Well, in these patents
8 thrombectomy refers to removal of thrombus from a
9 patient.

10 By MR. HAMILTON:

11 Q. And what's a thrombus?

12 A. A blood clot.

13 Q. In the context of the technical field of
14 the patents at issue here, the '333, '910, and '580
15 patents, what does the term mechanical thrombectomy
16 mean?

17 MR. STOWELL: Objection. Lack of
18 foundation.

19 THE WITNESS: I think it just means
20 removing a clot from the patient.

21 By MR. HAMILTON:

22 Q. What's the difference between mechanical
23 thrombectomy and thrombectomy?

24 A. I think they both describe removing
25 thrombus from a patient.

1 Q. Is there any difference between those two
2 terms?

3 A. I'm not sure. I would have to look at the
4 patents in question to see if they differentiate
5 those two terms.

6 Q. So as an -- do you believe you are an
7 expert in the technical field of the '333, '910, and
8 '580 patents?

9 A. Yes, I believe I meet the definition of --
10 that is proposed in paragraph 7 that we're
11 discussing.

12 Q. And as an expert in the field of the '333,
13 '910, and '580 patents, are you telling me you
14 can't -- you don't know the difference between a
15 mechanical thrombectomy and a thrombectomy?

16 MR. STOWELL: Objection. Lack of
17 foundation. Asked and answered.

18 THE WITNESS: I'm not sure if the patents
19 describe them differently.

20 By MR. HAMILTON:

21 Q. So if patents don't describe them
22 differently, is it your understanding that those
23 terms mean the same thing?

24 A. I think mechanical thrombectomy is just a
25 more specific description of using mechanical means

1 or aspiration means to remove thrombus from a
2 patient.

3 Q. So a mechanical thrombectomy is a subset of
4 thrombectomy; is that right? It's a specific type
5 of thrombectomy?

6 A. I think they're using it as a more specific
7 description of removing thrombus from a patient.

8 Q. By more specific you mean using some kind
9 of mechanical means; is that right?

10 A. That's what the term mechanical would
11 imply.

12 Q. Other than mechanical thrombectomy, are
13 there other types of thrombectomy?

14 A. Well certainly surgeons have done open
15 procedures to remove thrombus from patients. I'm
16 not sure if a surgeon would consider that mechanical
17 thrombectomy or surgical thrombectomy. Either way,
18 you're removing thrombus from a patient.

19 Q. What's the difference between mechanical
20 thrombectomy and surgical thrombectomy?

21 A. Example I gave was a surgeon who has the
22 vessel opened or the heart opened in order to remove
23 the thrombectomy directly with direct vision. I
24 might still consider that mechanical thrombectomy if
25 he's using a tool to remove a thrombus.

1	Q. Other than mechanical, surgical --	09:34:02
2	mechanical or surgical thrombectomy, are there any	09:34:06
3	other types of thrombectomy?	09:34:09
4	A. Well these patent talk about aspiration a	09:34:18
5	lot. I think that's a subset of mechanical	09:34:21
6	thrombectomy.	09:34:23
7	Q. Other than surgical, mechanical,	09:34:25
8	aspirational, are there any other types of	09:34:28
9	thrombectomy?	09:34:30
10	A. There may be. I'm not sure that the	09:34:32
11	patents describe others.	09:34:33
12	Q. Are you aware of any others?	09:34:35
13	A. Yeah, I'm not sure if there are others or	09:34:53
14	not, other categories that physicians may term --	09:34:56
15	use different terms for removing thrombus.	09:35:00
16	Q. What is -- what do you mean by "removing	09:35:06
17	thrombus?"	09:35:08
18	A. Thrombectomy is the act of removing	09:35:11
19	thrombus from a patient.	09:35:13
20	Q. Is there a term in the art -- when I say	09:36:16
21	"the art," the field of the '333, '910, and '580	09:36:20
22	patents, for preventing a formation of a thrombus?	09:36:24
23	A. Certainly there are pharmaceuticals that	09:36:53
24	are given to patients to prevent thrombus	09:36:56
25	formations.	09:36:59

1 Q. Is there a term for taking steps to prevent
2 the formation of a thrombus in a patient?

3 A. Patients are given anticoagulants,
4 antiplatelet medications. There probably are other
5 categories of medicines that are given to patients
6 to prevent formation of thrombus.

7 Q. Are you familiar with the firm -- excuse
8 me -- the term thrombogenicity?

9 A. Yes.

10 Q. What does that term mean?

11 A. Usually refers to materials that might be
12 more prone to develop thrombus on their surface
13 would be higher in its thrombogenicity potential.

14 Q. When you say materials that are more likely
15 to -- did you say form a thrombus on their surface?
16 Is that how you termed it?

17 A. I would have to read back the exact words I
18 used. I'm not sure exactly how I termed it.

19 Q. Is that an issue when -- where is that an
20 issue in the design of medical devices?

21 MR. STOWELL: Objection. Vague.

22 THE WITNESS: Can you re-ask the question?

23 By MR. HAMILTON:

24 Q. In your experience, would a person of
25 ordinary skill in the art look to prevent the

1 formation of a thrombus on the surface of the 09:39:53
2 material in designing a medical device? 09:39:55

3 A. Yes, certainly that is a design 09:40:02
4 consideration in the products that I've worked on 09:40:05
5 that are all blood contacting devices, whether they 09:40:08
6 were temporary blood contacting devices like 09:40:13
7 short-term use catheters or whether they were 09:40:18
8 long-term permanent implants. 09:40:21

9 Q. Would you consider that formation of a 09:40:26
10 thrombus a negative side effect from a medical 09:40:30
11 device? 09:40:33

12 A. Certainly it -- it can result in 09:40:43
13 complications to the patient if it's -- if a 09:40:45
14 thrombus is formed and emboli are created. 09:40:48

15 Q. And you had said in devices you designed 09:40:53
16 that's a consideration; is that right? 09:40:56

17 Let me just -- I said you designed -- you 09:41:02
18 have designed in the past -- let me just clarify 09:41:07
19 that -- that has been a consideration; correct? 09:41:10

20 A. Yeah, as I state on page 4, paragraph 9, I 09:41:20
21 described a number of devices on which I have worked 09:41:28
22 over the years. All of -- all of these devices were 09:41:31
23 in blood contact, and choosing materials that were 09:41:35
24 biocompatible was a key component of these projects. 09:41:39
25 Knowledge of the potential complications related to 09:41:43

1 blood clots, thrombus, thromboemboli was a critical
2 part of every project I worked on.

3 Q. For the devices you've designed, were there
4 other complications -- potential complications?

5 A. Every medical device has multiple potential
6 complications.

7 Q. And did you take steps to prevent those
8 other complications when designing the device?

9 A. We certainly took steps to design devices
10 appropriately for the application to minimize the
11 chance of any patient complication.

12 Q. So if you look at paragraph 10 of your
13 declaration, the last sentence, you see reference to
14 the MitraClip device?

15 A. Yes.

16 Q. Is the MitraClip device designed to remove
17 a thrombus or a blood clot?

18 A. No.

19 Q. So is it fair to say that your
20 consideration of a thrombus embolism or blood clot
21 when designing the MitraClip device consisted of
22 evaluating the device's potential to cause a
23 thromboembolism; is that right?

24 A. We certainly iterated the design and made
25 modifications in order to minimize the likelihood of

1 thrombus developing on the device. We certainly 09:44:49
2 tested it in animals and bench studies before use in 09:44:54
3 patients. 09:45:03

4 Q. And did that -- any of that work include 09:45:04
5 using the MitraClip device to perform a 09:45:10
6 thrombectomy? 09:45:15

7 A. No. We did not perform thrombectomy with 09:45:15
8 the MitraClip device. It was used to treat patients 09:45:18
9 with mitral valve regurgitation using a catheter 09:45:21
10 based system. 09:45:26

11 Q. So is it fair to say your extent -- the 09:45:34
12 extent of your experience related to thrombectomy -- 09:45:37
13 let me -- let me rephrase that. 09:45:40

14 Is it fair to say the extent of your 09:45:42
15 experience gathered from your work with the 09:45:44
16 MitraClip device is the prevention of the formation 09:45:45
17 of a thrombus? 09:45:51

18 A. There were many, many design considerations 09:45:58
19 in play during development of the MitraClip system, 09:46:04
20 the catheters, the clip, et cetera, the physician 09:46:08
21 use of the device. Minimizing thrombosis of the 09:46:12
22 device was one of many important design 09:46:19
23 considerations. 09:46:22

24 Q. And did any of those design considerations 09:46:25
25 include performing a thrombectomy? 09:46:28

1 A. We did not perform thrombectomy with the
2 MitraClip device.

3 Q. Do you believe your experience with the
4 MitraClip device design and its potential to cause
5 thromboembolism makes you an expert in
6 thrombectomy?

7 A. I believe that my experience in developing
8 the many different devices that I list on section 9,
9 from thermodilution catheters to left ventricular
10 assist devices, a centrifugal blood pump for bypass
11 procedures, angioplasty catheters, abdominal aortic
12 aneurysm implants, and the MitraClip device, plus
13 some other devices I worked on that I neglected to
14 mention, certainly provides comparable industry
15 experience as the patent owner proposed for the
16 person of ordinary skill in the art definition as
17 shown on paragraph 6.

18 Q. Do you believe you're an expert in
19 thrombectomy?

20 A. I believe my comparable industry experience
21 gives me enough expertise to evaluate the content of
22 these patents and the claims involved.

23 Q. And do you believe you're an expert in
24 thrombectomy?

25 A. Can you read back what I just said.

1 MR. STOWELL: Objection. Asked and
2 answered.

3 By MR. HAMILTON:

4 Q. I'm sorry. Are you finished with your
5 answer?

6 A. If you can read back what I just said.

7 Q. Do you believe you are an expert in
8 thrombectomy?

9 MR. STOWELL: Objection. Asked and
10 answered.

11 THE WITNESS: I think my comparable
12 industry experience provides sufficient expertise to
13 evaluate these patents at issue here.

14 By MR. HAMILTON:

15 Q. Do you believe you're an expert in
16 mechanical thrombectomy?

17 A. Same answer.

18 Q. In designing the MitraClip device, you had
19 said one of the complications is its potential to
20 cause thromboembolism; is that right?

21 A. Yes.

22 Q. Are there other complications that can --
23 that the -- the MitraClip device may cause?

24 A. Well if you read the instructions for use,
25 there are probably dozens of potential complications

1 listed in that IFU. So, yes, there are many
2 others.

3 Q. And in designing the MitraClip device, did
4 you take into account how to prevent those
5 complications or mitigate those complications?

6 A. Certainly that was the goal of the
7 engineers and the clinical team, to minimize patient
8 complications while achieving the intended clinical
9 result.

10 Q. And you said there were many; is that
11 right?

12 A. There are many potential complications
13 during the procedure of a MitraClip device which are
14 outlined in the instructions for use.

15 Q. About how many do you think?

16 A. I would have to look at the instructions.

17 Q. And is potential to cause thrombo --
18 thromboembolism one of those many?

19 A. Yes, it is.

20 Q. And do you believe because -- withdraw the
21 question.

22 I'm going to hand you what's been
23 previously marked as Exhibit 1075 in IPR2025-01025.

24 Do you see the document?

25 A. Exhibit 1075?

1	Q. Yes.	09:52:20
2	A. Is that what you said? Yes.	09:52:20
3	Q. Do you recognize this document?	09:52:23
4	A. Yes. It's the MitraClip delivery system	09:52:27
5	instructions for use. It looks like it's from 2013	09:52:33
6	based on the sub -- subscript.	09:52:37
7	Q. If you take a look at what's labeled page 6	09:52:46
8	of 54. Is this a list of potential complications in	09:52:49
9	adverse events that you took into account when	09:53:05
10	designing the MitraClip device?	09:53:08
11	A. It is the list of potential complications	09:53:16
12	in adverse events -- potentially anticipated events.	09:53:18
13	Many of these are clinically related, not	09:53:24
14	necessarily directly related to designing the	09:53:28
15	device.	09:53:30
16	Q. What do you mean "clinically related"	09:53:32
17	versus "not necessarily directly related to	09:53:35
18	designing the device?" What's the difference?	09:53:38
19	A. For instance, it lists fever. It lists it	09:53:55
20	dyspnea. These are not necessarily caused by the	09:54:03
21	device. It could be more related -- many of these	09:54:16
22	are related more to the recovery after the procedure	09:54:20
23	being on general anesthesia, for instance.	09:54:22
24	Q. Did you consider all of these potential	09:54:32
25	complications in adverse events when designing the	09:54:34

1	MitraClip device?	09:54:39
2	A. Not all of them, no.	09:54:53
3	Q. Which ones did you consider?	09:54:58
4	A. I'm not sure. I know we didn't consider	09:55:01
5	things like urinary tract infection. That's related	09:55:03
6	to the procedure of putting in a drainage catheter	09:55:08
7	during the procedure, it's not related to performing	09:55:13
8	the procedure so we would not have considered that	09:55:17
9	as an example when designing the MitraClip device.	09:55:20
10	Q. Can you identify any of these potential	09:55:29
11	complications in adverse events that you did	09:55:32
12	consider when designing the MitraClip device?	09:55:34
13	A. Yes.	09:55:38
14	Q. Which ones?	09:55:39
15	A. Allergic reaction. Arrhythmias. Atrial	09:55:44
16	fibrillation. Atrial septal defect. AV fistula.	09:55:52
17	Bleeding. Cardiac perforation. Cardiac tamponade.	09:56:04
18	Pericardial effusion. MitraClip erosion, migration,	09:56:19
19	malposition. MitraClip device thrombosis.	09:56:25
20	MitraClip system component embolization. Conversion	09:56:31
21	to standard valve surgery. Dislodgement of	09:56:43
22	previously implanted devices. Emboli. Emergency	09:56:54
23	cardiac surgery. Failure to deliver MitraClip to	09:57:05
24	the intended site. Failure to retrieve MitraClip	09:57:39
25	system components. Hematoma. Hemolysis.	09:57:43

1 Hypotension, hypertension. Infection at the 09:58:08
2 insertion site, infection at the incision site was 09:58:20
3 considered by way of performing sterilization 09:58:26
4 validation. Injury to the mitral valve. Mitral 09:58:31
5 stenosis. Mitral valve injury. Myocardial 09:58:43
6 infarction. Peripheral ischemia I guess we 09:59:07
7 considered as it relates to the diameter of the 09:59:18
8 sheath that went into the leg. Prolonged 09:59:22
9 ventilation I guess we considered from the 09:59:38
10 standpoint of wanting a reasonably short procedure 09:59:40
11 time. Single leaflet device attachment. Stroke or 09:59:43
12 TIA. Vascular trauma dissection or occlusion. 10:00:15
13 Vessel spasm. Vessel perforation or laceration. 10:00:24
14 Worsening mitral regurgitation. That's it. 10:00:31

15 Q. So let's start with the -- the first one on 10:00:51
16 that list, allergic reaction. What did you do when 10:00:53
17 designing the MitraClip with respect to considering 10:01:01
18 allergic reaction? 10:01:08

19 A. We chose materials that were known to be 10:01:16
20 biocompatible and we performed testing to look at 10:01:22
21 nickel -- nickel and other elements that might come 10:01:35
22 out of the metal components. 10:01:42

23 Q. So it would be fair to say that you 10:01:49
24 attempted to design the device to minimize causing 10:01:52
25 allergic reaction? 10:01:59

1	A. Yes.	10:02:00
2	Q. Did you design the device to treat an	10:02:04
3	allergic reaction?	10:02:06
4	A. No.	10:02:08
5	Q. Do you believe you're an expert in treating	10:02:09
6	allergic reactions?	10:02:12
7	A. No.	10:02:14
8	Q. So just because you designed the device to	10:02:16
9	prevent or reduce the chances of a complication	10:02:21
10	doesn't mean you're an expert in treating that	10:02:24
11	complication, does it?	10:02:26
12	MR. STOWELL: Objection. Vague.	10:02:28
13	THE WITNESS: Designing a device to	10:02:38
14	minimize these complications was a normal part of	10:02:39
15	the engineering development experience.	10:02:47
16	By MR. HAMILTON:	10:02:50
17	Q. Is it fair to say that designing a device	10:02:50
18	to minimize a complication does not make you an	10:02:52
19	expert in treating that complication, does it?	10:02:55
20	MR. STOWELL: Objection. Vague.	10:02:57
21	THE WITNESS: Depends on the	10:03:02
22	complication.	10:03:03
23	By MR. HAMILTON:	10:03:15
24	Q. So for allergic reactions -- you've said it	10:03:15
25	doesn't make you an expert in treating allergic	10:03:18

1	reactions; right?	10:03:21
2	A. I'm not an allergist, no.	10:03:23
3	Q. What about arrhythmias? Are you an expert	10:03:25
4	in treating arrhythmias?	10:03:30
5	A. No.	10:03:32
6	Q. What about atrial fibrillation? Are you an	10:03:33
7	expert in treating atrial fibrillation?	10:03:38
8	A. No.	10:03:41
9	Q. If you go down to -- I will withdraw the	10:03:59
10	question.	10:04:05
11	If you turn to page 3 of 54 of that same	10:04:34
12	document, Exhibit 1075. Do you see	10:04:39
13	contraindications?	10:04:46
14	A. Yes.	10:04:48
15	Q. What does that mean, contraindications?	10:04:49
16	A. Well in the world of instructions for	10:04:55
17	medical devices, there is an indication for how it	10:04:58
18	should be used and there are specific	10:05:01
19	contraindications where the device should not be	10:05:04
20	used.	10:05:09
21	Q. What does that mean "where the device	10:05:11
22	should not be used?" What do you mean by that?	10:05:13
23	A. In patients for whom the device is not	10:05:16
24	indicated.	10:05:19
25	Q. So if you look at the last bullet point	10:05:20

1	there. Do you see that bullet point?	10:05:22
2	A. Yes.	10:05:24
3	Q. What does that mean?	10:05:31
4	A. It says, "Evidence of intracardiac inferior	10:05:34
5	vena cava or femoral venous thrombus." That means	10:05:38
6	if patients are -- present -- I'm sorry. If	10:05:44
7	patients present with evidence of thrombus in the	10:05:48
8	cardiac chambers, the IVC, or in the femoral vein	10:05:54
9	where the doctor is going to insert the device, that	10:06:00
10	this is not a patient that should be treated with a	10:06:02
11	MitraClip system.	10:06:05
12	Q. And why not?	10:06:28
13	A. If there is thrombus in the femoral vein,	10:06:34
14	it could get dislodged when trying to advance the	10:06:37
15	delivery system. If there's thrombus -- massive	10:06:41
16	thrombus in the cardiac chambers, it could get	10:06:47
17	dislodged during the procedure.	10:06:51
18	Q. So you mentioned cardiac chambers, femoral	10:07:01
19	vein; is that right?	10:07:06
20	A. Yes. Intracardiac thrombus, inferior vena	10:07:09
21	cava thrombus, or femoral vein thrombus are the	10:07:14
22	three contraindications listed there.	10:07:16
23	Q. And would any of those include pulmonary	10:07:20
24	embolisms?	10:07:24
25	A. We didn't list that there, no.	10:07:25

1 Q. And is it your understanding that those 10:07:27
2 three terms don't include a pulmonary embolism? 10:07:29

3 A. Correct. Those three terms do not. 10:07:39

4 Q. Would it include a deep vein thrombosis? 10:07:51

5 A. Femoral venous thrombosis could -- could be 10:08:10
6 a deep vein thrombosis, yes. 10:08:14

7 Q. If you go to paragraph 7, I'm going to ask 10:09:13
8 you a question about page 3 of your '910 10:09:18
9 supplemental declaration. Let me know when you're 10:09:24
10 ready for the question. 10:09:42

11 What are the primary components of an 10:09:59
12 aspiration system for mechanical thrombectomy? 10:10:02

13 A. I think it depends a bit on the system, but 10:10:19
14 generally for the thrombectomy systems in -- at 10:10:22
15 issue in these patents, there's the thrombectomy 10:10:27
16 catheter, syringes, potentially pumps, filters, 10:10:36
17 collection chambers. Depends on the procedure. If 10:10:47
18 they are using a stentriever type device, then it 10:10:56
19 would involve another catheter system like a 10:11:01
20 stentriever, for instance. 10:11:04

21 Q. What about valves, would that be a primary 10:11:13
22 component of a aspiration system for a mechanical 10:11:17
23 thrombectomy? 10:11:21

24 A. I think it depends on the system that the 10:11:27
25 physician is using but certainly valves like 10:11:28

1 stopcocks are used in many of these types of systems 10:11:33
2 and all types of medical procedures. 10:11:37

3 Q. So then would you consider a valve a 10:11:45
4 primary component of an aspirational system for 10:11:47
5 mechanical thrombectomy? 10:11:52

6 A. I think it depends on the system in 10:11:55
7 question, whether they use a valve or not. 10:11:57

8 Q. So if you go to the last sentence in that 10:12:05
9 paragraph 7, it says, "because the catheter is a 10:12:09
10 primary component of any aspiration system." 10:12:14

11 Do you see that? 10:12:17

12 A. Yes. 10:12:18

13 Q. I'm trying to figure out what are the other 10:12:19
14 primary components of any aspiration system. And 10:12:21
15 you had said pumps, collection chambers, syringes, 10:12:25
16 filters, maybe valves. Are there any others? 10:12:31

17 MR. STOWELL: Objection. Misstates the 10:12:36
18 testimony. 10:12:38

19 THE WITNESS: I think what my sentence -- 10:12:44
20 the last sentence says, "the catheter is a primary 10:12:45
21 component of any aspiration system." The other 10:12:49
22 components that I mentioned like filters, they don't 10:12:52
23 have to use a filter if they're not returning blood 10:12:54
24 to the patient, for instance. Pumps. They could 10:12:58
25 use a syringe. They don't need electric pump, for 10:13:01

1 instance, during aspiration thrombectomy procedures.

10:13:05

2 So the common -- certainly the common component is

10:13:12

3 the catheter itself. Items like syringes and

10:13:14

4 stopcocks are very standard procedure so I'm not

10:13:21

5 could say it was primary -- of primary importance.

10:13:24

6 By MR. HAMILTON:

10:13:30

7 Q. Are there any components that are primary
8 components of a aspiration system for mechanical
9 thrombectomy besides a catheter?

10:13:30

10:13:32

10:13:35

10 A. Certainly depends on the type of
11 thrombectomy that's being performed. If it's purely
12 aspiration, the catheter is a primary component, a
13 vacuum source is a primary component, and maybe
14 there are others that could be considered.

10:13:39

10:13:41

10:13:44

10:13:50

10:13:55

15 Q. You have said -- one of the terms used was
16 collection chamber. What did you mean by that?

10:14:34

10:14:37

17 A. Well the term canister is used frequently
18 for aspiration type systems, collection canisters.
19 Commercial devices tend to use that term for
20 aspiration systems. That's where the blood is
21 collected after aspirating from the patient.

10:14:53

10:14:56

10:15:03

10:15:07

10:15:17

22 Q. Is a collection chamber a required
23 component of an aspiration system for mechanical
24 thrombectomy?

10:15:31

10:15:33

10:15:37

25 A. For aspiration thrombectomy using a

10:15:49

1 syringe, I guess a syringe would be considered the 10:15:52
2 collection canister. 10:15:55

3 Q. Are you finished with your answer? 10:16:21

4 A. Yes. 10:16:23

5 Q. Is a collection chamber necessary in an 10:16:23
6 aspiration system for mechanical thrombectomy? 10:16:35

7 A. Depends on the system that the physician is 10:16:41
8 using. There may be systems where the blood is 10:16:42
9 withdrawn and -- and provided back to the patients. 10:16:47
10 I think in -- even in those systems there is a 10:16:54
11 filter -- blood would go through a filter before 10:16:57
12 providing it back to the patient. 10:17:01

13 Q. If you turn to paragraph 11 of that same 10:17:30
14 declaration, '910 supplemental declaration. 10:17:33

15 A. Paragraph 11 or page 11? 10:17:40

16 Q. Paragraph 11 that is on page 5. And four, 10:17:42
17 five -- six lines down at the end of that sixth line 10:17:52
18 there is that term thrombogenicity. Is that how you 10:17:56
19 pronounce that term? 10:18:01

20 A. Yes. 10:18:02

21 Q. In designing the MitraClip device, was that 10:18:11
22 the primary concern related to the formation of a 10:18:25
23 thrombus that you considered? 10:18:28

24 A. Well that's certainly the primary test that 10:18:49
25 is performed to confirm that the device meets the 10:18:51

1 requirements for thrombogenicity. 10:18:54

2 Q. So other than considering whether the 10:19:04
3 device the MitraClip, I believe you said meets the 10:19:07
4 test for thrombogenicity, did you consider any other 10:19:11
5 aspect of that device with respect to its potential 10:19:16
6 to cause a thrombus? 10:19:18

7 A. Yes. For example in paragraph 12 toward 10:19:38
8 the end I list that "In prior iterations of the 10:19:45
9 MitraClip our engineering team experimented with 10:19:50
10 uncovered metal components, different shapes of 10:19:53
11 metal components" -- that's not a direct quote -- 10:19:56
12 "and alternative covering materials in order to 10:19:59
13 minimize the buildup of thrombus on the implant." 10:20:06

14 Q. And is that different than 10:20:10
15 thrombogenicity? 10:20:13

16 A. Well, the real test for thrombogenicity on 10:20:21
17 the implant is really acute animal studies -- 10:20:25
18 sorry -- chronic animal studies -- acute and chronic 10:20:28
19 animal studies can show areas of thrombus 10:20:32
20 accumulation. The thrombogenicity testing that was 10:20:36
21 done per an ISO requirement, ISO 10993, is a more -- 10:20:44
22 it's more of a bench test evaluation. 10:20:56

23 Q. So then is it fair to say that your work 10:21:15
24 with the MitraClip in preventing the formation of a 10:21:18
25 thrombus related to whether the device would cause 10:21:23

1 the formation of a thrombus either from the 10:21:39
2 materials chosen or the shape of the device? 10:21:42

3 A. Surface finishes, the materials in contact 10:21:53
4 with the blood, and even on the catheter -- the 10:21:58
5 outside of the catheter, the smoothness of that is a 10:22:06
6 consideration for minimizing the development of 10:22:12
7 thrombus during the use. 10:22:16

8 Q. So then would it be fair to say that 10:22:21
9 you're -- the primary issue with respect to your 10:22:23
10 design of the MitraClip device was minimizing the 10:22:26
11 formation of a thrombus through the use of the 10:22:30
12 device or components associated with the device? 10:22:33

13 A. Primary development aspects of the 10:22:38
14 MitraClip device were to be able to deploy it on the 10:22:40
15 mitral leaflets appropriately to actuate the device, 10:22:46
16 open and close and be able to remove the device, to 10:22:54
17 be able to lock the device permanently on the micro 10:22:58
18 leaflets, to be able to detach the device from the 10:23:01
19 delivery system. We had a whole long list of design 10:23:08
20 requirements, one of which was that it should be 10:23:10
21 non-thrombogenic. 10:23:13

22 Q. Were any of those design requirements 10:23:19
23 related to the formation of a thrombus other than 10:23:22
24 that you could use the device and make sure it's 10:23:28
25 non-thrombogenic? 10:23:30

1 A. Certainly we had design requirements around 10:23:33
2 minimizing thrombogenicity. Yes. 10:23:38

3 Q. So other than minimizing or preventing 10:24:13
4 the -- excuse me -- the formation of a thrombus, 10:24:16
5 what other design considerations related to a 10:24:21
6 thrombus with respect to designing the MitraClip 10:24:25
7 device? 10:24:29

8 A. We certainly had requirements to be -- I'll 10:24:43
9 start again. 10:24:45

10 We certainly had requirements relating to 10:24:46
11 flushing through the lumens of the catheter to 10:24:49
12 prevent blood from stagnating inside the small 10:24:54
13 lumens of the catheter. That's another example of 10:24:57
14 working to minimize thrombus on the system or in the 10:25:03
15 system. 10:25:08

16 Q. What's the issue -- and that -- and that 10:25:09
17 was to prevent the formation of a thrombus; 10:25:12
18 correct? 10:25:15

19 A. Yes, we had to be able to flush through the 10:25:17
20 lumens of a delivery catheter, for instance. 10:25:19

21 Q. How does stagnation of blood relate to the 10:25:23
22 formation of a thrombus? 10:25:25

23 A. Blood can clot when it -- when it's in a 10:25:34
24 stagnant location for a long time. These patients 10:25:37
25 are well heparinized during procedure -- before, 10:25:40

1 during, and after the procedure, but still that was 10:25:45
2 a design consideration. 10:25:48

3 Q. So that you -- you wanted to prevent the 10:25:52
4 stagnation of blood; is that correct? 10:25:55

5 A. We needed -- we wanted to be able to have a 10:25:57
6 constant flush of heparinized saline through the 10:26:00
7 catheter so that blood did not get in the lumens 10:26:05
8 partly for -- well I will say primarily for keeping 10:26:09
9 those lumens free of blood so that the actuation 10:26:17
10 mechanisms, we had cables and pull lines within 10:26:27
11 those lumens, so that those could still work 10:26:30
12 appropriately so we needed to be able to flush 10:26:35
13 heparinized saline through the system constantly. 10:26:38

14 Q. If you look at paragraph 13, first 10:27:03
15 sentence. You recite, "I was also an author of the 10:27:10
16 MitraClip chronic animal study results published in 10:27:16
17 the journal Circulation." 10:27:20

18 Do you see that? 10:27:21

19 A. Yes. 10:27:22

20 Q. What did you mean by that? 10:27:23

21 A. That I was one of the authors of that 10:27:29
22 chronic animal study result -- chronic animal study 10:27:31
23 whose results were published in Circulation 10:27:34
24 magazine -- Circulation journal. 10:27:37

25 Q. I'm going to hand you another document. 10:27:48

1 This is Exhibit 1078 from IPR2025-01025.

10:27:53

2 Is this the article you reference in
3 paragraph 13 of your -- your '910 supplemental
4 declaration?

10:28:05

10:28:07

10:28:11

5 A. I'm not sure because my name is not listed
6 as an author. It does look like the one that we
7 provided as Exhibit 1078 but I'm not listed as an
8 author here. I may have provided the wrong
9 reference to the patent asset.

10:28:28

10:28:30

10:29:22

10:29:25

10:29:27

10 Q. So just to be clear, in paragraph 13 you
11 cite Exhibit 1078 stating that you are an author,
12 but for the Exhibit 1078 you are not an author of
13 that article; correct?

10:29:33

10:29:38

10:29:44

10:29:48

14 A. Correct. I'm not listed as an author of
15 this Exhibit 1078 which could have been a mistake on
16 my part. I would have to go back and double-check
17 some other publications. Having said that, I was
18 certainly involved with the entire study. This
19 referenced I was -- approved the protocols and the
20 reports and was at probably all of these clip
21 implants and probably almost all of the clip
22 ex-plants so I'm quite familiar with the -- the
23 study that's described here.

10:29:56

10:29:59

10:30:02

10:30:07

10:30:27

10:30:32

10:30:35

10:30:42

10:30:45

10:30:47

24 Q. But you're not an author of that study;
25 correct?

10:30:51

10:30:54

1 A. I'm not listed as an author on this study,
2 that's correct.

3 Q. Do you believe you should be listed as an
4 author of Exhibit 1078?

5 A. No. I think the mistake is either I
6 provided a different reference -- I provided this
7 reference in error to counsel or I mistakenly
8 thought I was an author.

9 Q. If you would look at paragraph 14 of your
10 '910 supplemental declaration. That's also on page
11 6. You reference work that led to the development
12 of a novel stent graph to treat abdominal aortic
13 aneurysms.

14 Do you see that?

15 A. Yes.

16 Q. Did your work described in paragraph 14
17 relate to designing a device to perform a
18 thrombectomy?

19 A. No. The device was used to treat abdominal
20 aortic aneurysms with a catheter based system
21 instead of open -- open belly surgery.

22 Q. And if you look at the next paragraph, 15,
23 and then I want to ask you a question about the
24 bullet point that's on page 7 in that paragraph.

25 A. Yes.

1	Q.	You see reference to a delivery catheter	10:33:14
2		that may be used to deliver other types of devices?	10:33:17
3		Do you see that?	10:33:21
4	A.	Yes.	10:33:23
5	Q.	Let me -- let me -- I want to give you the	10:33:35
6		document. I'm handing what's been marked as Exhibit	10:33:40
7		1079 in IPR2025-01025.	10:34:01
8		Do you recognize Exhibit 1079?	10:34:21
9	A.	Yes.	10:34:24
10	Q.	Is this the exhibit referenced in paragraph	10:34:28
11		15 of your '910 supplemental declaration?	10:34:30
12	A.	Yes.	10:34:37
13	Q.	And you are an author on this one;	10:34:38
14		correct?	10:34:40
15	A.	Yes.	10:34:41
16	Q.	If you want to turn to paragraph 245. This	10:34:49
17		is the paragraph that's partially quoted in	10:34:59
18		paragraph 15 of the '910 supplemental declaration.	10:35:00
19		Let me know when you're there and you're ready for a	10:35:05
20		question.	10:35:08
21	A.	Okay.	10:35:50
22	Q.	Does Exhibit 1079 disclose a device for the	10:36:04
23		treatment of a thrombus or embolism or blood clot?	10:36:11
24	MR. STOWELL:	Objection. Vague.	10:36:20
25	THE WITNESS:	Certainly the thrush --	10:36:35

1 sorry -- I mean thrust of this continuation -- this
2 continuation part in the claims are related to a
3 two-part steerable after system where one catheter
4 is, say, telescoped within the other and both
5 catheters have steerable capabilities in its design.
6 And in paragraph 245 we listed a number of different
7 potential applications for a nested or telescoped
8 two-part catheter system with steering. One of
9 those that we disclose in here is related to embolic
10 filtration and embolic removal, among a number of
11 other potential uses for this two-part catheter
12 system.

13 By MR. HAMILTON:

14 Q. And when you say uses for the two-part
15 system, you mean the ability of the delivery
16 catheter to deliver other devices; is that
17 correct?

18 A. Well certainly that sentence in 245 says
19 that "The delivery catheter of the present invention
20 may be used to deliver other types of devices,
21 particularly endovascular and minimally invasive
22 surgical devices used in angioplasty, et cetera, to
23 include the last items mentioned about -- I'm
24 sorry -- the prior item mentioned related to embolic
25 filtration and removal." And the sentence -- the

1 paragraph wraps up by saying, "Thus, the delivery
2 catheter may be used for applications in which a
3 highly flexible, kink-resistant device is desirable
4 with high compressive, tensile and torsional
5 strength."

6 Q. So does that mean that the delivery
7 catheter disclosed in Exhibit 1079 may be used to
8 deliver other devices to treat various conditions?

9 A. Well, the designs discussed here a two-part
10 steerable catheter system through which other
11 devices could be employed including a -- for
12 instance, a suction catheter, including a
13 stentriever, for instance.

14 Q. Do you believe that the fact that this
15 document discloses that its delivery catheter can be
16 used to deliver other devices, including devices for
17 embolic filtration removal, contributes to your
18 qualifications as an expert in thrombectomy?

19 A. I think it contributes to my experience in
20 comparable -- comparable design fields, comparable
21 industry experience related to catheter design and
22 procedures, yes.

23 Q. This same paragraph says that it can be
24 used -- that the delivery catheter may also be used
25 to deliver devices used in angioplasty.

1	Do you see that?	10:41:48
2	A. Yes.	10:41:50
3	Q. Do you believe that makes you qualified as	10:41:51
4	an expert in devices for angioplasty?	10:41:53
5	A. I'm not sure that sentence does but I have	10:42:03
6	developed balloon catheters used in angioplasty and	10:42:06
7	am quite familiar with the procedure and the	10:42:10
8	devices.	10:42:13
9	Q. But that sentence doesn't make you	10:42:14
10	qualified; correct? You need other experience;	10:42:16
11	correct?	10:42:19
12	A. I think what I said before was that	10:42:21
13	comparable industry experience is what I am -- is	10:42:23
14	what I have and it makes me expert enough to	10:42:30
15	evaluate these -- these types of patents.	10:42:34
16	Q. And one of the things that you refer to for	10:42:37
17	comparable industry experience is developing a	10:42:42
18	delivery catheter that can deliver all these	10:42:45
19	different types of devices; correct?	10:42:46
20	A. Certainly developing a two-part steerable	10:42:51
21	system is pretty extensive industry experience in	10:42:53
22	the catheter design world. And as we state, it	10:43:00
23	could be used for thrombectomy removing embolic	10:43:03
24	material.	10:43:08
25	Q. And it doesn't actually say it could be	10:43:11

1 used for that, it says it could be used to deliver a 10:43:13
2 device for that purpose; correct? 10:43:16

3 A. That's how the sentence is written. 10:43:19

4 Deliver a device to remove embolic material which 10:43:23
5 could be another vacuum kind of -- a single lumen 10:43:26
6 simple thrombectomy catheter could be advanced 10:43:32
7 through this two-part steerable system. 10:43:35

8 Q. And it has a long list of other devices 10:43:40
9 that could be delivered as well; correct? 10:43:42

10 A. There's a long list. 10:43:44

11 Q. And just because this delivery catheter set 10:43:45
12 forth in Exhibit 1079 can deliver other types of 10:43:50
13 devices doesn't necessarily make you an expert in 10:43:55
14 development of those other types of devices, does 10:43:59
15 it? 10:44:01

16 A. I think my -- this helps to confirm my 10:44:13
17 comparable industry experience as it relates to 10:44:18
18 thrombectomy procedures and devices. 10:44:22

19 Q. And -- and just to -- to -- to clarify, the 10:44:25
20 fact that you've developed a catheter that can 10:44:28
21 deliver a device to perform thrombectomy and many 10:44:31
22 other procedures contributes to your expertise in 10:44:34
23 mechanical thrombectomy; is that correct? Is that 10:44:38
24 your testimony? 10:44:41

25 A. I think my testimony includes the 10:44:44

1 description of the -- my comparable industry

10:44:50

2 experience as detailed through section -- I'm

10:44:58

3 sorry -- paragraph 9 through paragraph 18 of the

10:45:04

4 supplemental declaration '910. Excuse me.

10:45:15

5 MR. STOWELL: We have been going about an

10:45:28

6 hour and a half so whenever you get to a stopping

10:45:29

7 point.

10:45:32

8 By MR. HAMILTON:

10:45:33

9 Q. Do you need a break or a couple more

10:45:33

10 minutes?

10:45:36

11 A. As soon as possible, yeah.

10:45:36

12 Q. Okay. Why don't we take a break and then

10:45:37

13 we can come back.

10:45:39

14 THE VIDEOGRAPHER: We are going off the

10:45:41

15 record at 10:45.

10:45:42

16 (Recess.)

10:57:28

17 THE VIDEOGRAPHER: We are back on the

10:57:35

18 record at 10:57.

10:57:36

19 By MR. HAMILTON:

10:57:41

20 Q. Mr. Thornton, do you understand you are

10:57:41

21 still under oath?

10:57:43

22 A. Yes.

10:57:43

23 Q. Did you communicate with anyone in any way

10:57:48

24 during the break regarding the substance of this

10:57:50

25 matter?

10:57:52

1	A.	No.	10:57:53
2	Q.	Did you review any documents during the	10:57:55
3		break?	10:57:57
4	A.	No.	10:57:57
5	Q.	For this matter, do you bill your time by	10:58:08
6		the hour?	10:58:11
7	A.	Yes.	10:58:13
8	Q.	What's your hourly rate?	10:58:13
9	A.	\$500.	10:58:16
10	Q.	Has that rate changed since the onset of	10:58:18
11		this case?	10:58:20
12	A.	No.	10:58:21
13	Q.	Prior to the break we were looking at your	10:58:27
14		'910 supplemental declaration page 7. Do you see	10:58:32
15		the top bullet point on page 7?	10:58:40
16	A.	Yes.	10:58:43
17	Q.	Do you see the bold and italic phrase?	10:58:47
18	A.	Yes.	10:58:53
19	Q.	Does that mean preventing the formation of	10:58:53
20		the thrombus emboli or blood clot?	10:58:59
21	A.	Yeah. It says, reducing -- it says, "The	10:59:10
22		device 14 may have a smooth surface which prevents	10:59:16
23		cellular adhesion thereby reducing the accumulation	10:59:22
24		of cells having the potential -- I mean potential"	10:59:23
25		-- poorly written -- to form -- it should say to	10:59:26

1 form instead of for -- "form and emboli."

10:59:31

2 Q. So does that mean reducing the formation of
3 a thrombus clot or emboli?

10:59:46

10:59:56

4 A. Well, certainly thrombus -- the goal was to
5 prevent accumulative cells which would cause a
6 thrombus. A thrombus which releases into the
7 patient is generally termed an emboli.

11:00:02

11:00:06

11:00:09

11:00:13

8 Q. Does that phrase relate to removing or
9 treating an already formed thrombus emboli or
10 clot?

11:00:20

11:00:27

11:00:31

11 A. No. It's discussing preventing a thrombus
12 from forming in or on a device.

11:00:35

11:00:40

13 Q. And then if you look at paragraph 16. Same
14 questions. Does this discussion relate to
15 preventing or reducing the chances of the formation
16 of a thrombus clot or emboli?

11:00:43

11:00:54

11:00:58

11:01:02

17 A. Yes. Certainly in this patent publication
18 '721 we discuss the issues of current stem designs
19 which included the use of thrombogenic materials
20 which are exposed to blood and may lead to
21 thromboembolism.

11:01:12

11:01:16

11:01:23

11:01:26

11:01:30

22 Q. Does the discussion in this paragraph 16
23 relate to the removal or treatment of an already
24 formed thrombus emboli or clot?

11:01:39

11:01:40

11:01:42

25 A. No. We're discussing the prevention of

11:01:56

1 clot that may lead to thromboembolism. 11:02:02

2 Q. If you turn to paragraph 12. Same 11:02:06
3 questions. I'll just -- I'll just go to the second 11:02:17
4 one. Does -- does your discussion in paragraph 12 11:02:19
5 relate to the removal or treatment of an already 11:02:22
6 formed thrombus emboli or clot? 11:02:24

7 A. No. As the last sentence says, it relates 11:02:30
8 to preventing the development of thrombus on the 11:02:33
9 device. 11:02:36

10 Q. If you go to paragraph 17. Same question. 11:02:50
11 Does the discussion in this paragraph relate to the 11:02:56
12 removal or treatment of an already formed thrombus, 11:03:01
13 emboli, or clot? 11:03:04

14 A. No. It discusses the prevention -- it 11:03:14
15 discusses potential site for thrombogenic material 11:03:19
16 to build up and how we design the device so that 11:03:23
17 that did not form a wrinkle. 11:03:30

18 Q. And then paragraph 18. Same question. 11:03:36
19 Does the discussion in paragraph 18 relate to the 11:03:39
20 removal or treatment of an already formed thrombus, 11:03:43
21 emboli, or clot? 11:03:46

22 A. No. This is discussing the importance of 11:03:53
23 avoiding the buildup of thrombogenic material which 11:03:55
24 could lead to thromboembolism. 11:04:00

25 Q. If you look at the last sentence in that 11:04:06

1 paragraph. How does -- that the catheter may be 11:04:08
2 outside of the blood flow path which may reduce -- 11:04:27
3 how does that contribute to reducing clotting and 11:04:31
4 hemolysis during the use of the blood flow control 11:04:36
5 device? 11:04:40

6 A. I would have to look at the patent to be 11:05:18
7 more specific, but for this project I was developing 11:05:20
8 a device that was better than something that was 11:05:25
9 already out there which had a number of control 11:05:31
10 wires and the catheter itself down the center of the 11:05:36
11 flow channel, and my design put the catheter on the 11:05:40
12 outside of the flow channel and all the control 11:05:50
13 wires to control the blood controller -- blood flow 11:05:53
14 control device were outside of the blood flow path 11:05:59
15 thereby reducing the likelihood of thromboembolism 11:06:06
16 or hemolysis of the blood flowing through the 11:06:16
17 device. 11:06:21

18 Q. Does that mean that the -- these portions 11:06:28
19 of the catheter that you reference here don't 11:06:31
20 contact blood? 11:06:34

21 A. No, they are in blood contact but most of 11:06:39
22 the blood is flowing through the inside of this 11:06:49
23 ePTFE liner, let's say. 11:06:56

24 Q. So how does having portions of the catheter 11:07:06
25 that are in contact with blood but are outside the 11:07:10

1 flow path -- the blood flow path, excuse me,

11:07:13

2 contribute to reducing blood clot or hemolysis?

11:07:18

3 A. Because I'm comparing to a similar but

11:07:25

4 different device which has numerous wires in the

11:07:27

5 flow path and the delivery catheter itself -- I'm

11:07:31

6 sorry -- the guidewire lumen of the catheter itself

11:07:34

7 also in the center of the flow path. So getting rid

11:07:39

8 of all that mass of material that's in the flow path

11:07:42

9 of the large lumen, which is the size of the

11:07:45

10 inferior vena cava, should decrease the risk of any

11:07:52

11 hemolysis or thromboembolic material.

11:07:59

12 Q. And is that because those portions of the

11:08:04

13 catheter don't disrupt the flow path or interfere

11:08:07

14 with the flow path? Is that a fair statement?

11:08:11

15 A. Yes. Those wires in the catheter are

11:08:20

16 disrupting the flow path to some extent so removing

11:08:25

17 those I thought was a good -- a good idea.

11:08:29

18 Q. So earlier we had discussed that if blood

11:09:04

19 remained stagnant it's more likely to form a clot;

11:09:11

20 is that correct?

11:09:14

21 A. I think it can happen, yes.

11:09:18

22 Q. Does this sentence at the end of paragraph

11:09:20

23 18 relate to blood being stagnant?

11:09:24

24 A. Not necessarily. It's really relating to

11:09:33

25 removing the multiple wires and the guidewire lumen

11:09:35

1 of the catheter that exists in a different device. 11:09:39

2 Q. So then would it be fair to say that 11:09:44

3 disrupting blood flow, for example, causing -- I'll 11:09:54

4 withdraw the question. Let me rephrase that. 11:10:01

5 So in the prior art device, those wires and 11:10:14

6 other components, they would disturb the blood flow, 11:10:16

7 maybe cause turbulent flow or something else; is 11:10:19

8 that -- is that fair? 11:10:23

9 A. I certainly think they were a site for 11:10:27

10 potential thrombus buildup. In fact, the prior art 11:10:30

11 device I had seen photos at a presentation showing a 11:10:36

12 bunch of blood clot on these wires after it was 11:10:40

13 taken out of a patient. 11:10:44

14 Q. And -- and why -- why are they -- they a 11:10:45

15 location that is more likely to have buildup of a 11:10:47

16 thrombus? Is that because the blood flow is 11:10:52

17 disrupted by those wires or is it something else? 11:10:55

18 A. I'm not sure if it was the material choices 11:11:09

19 of change in the fluid -- fluid mechanics involved 11:11:11

20 to flow around those wires, but removing those wires 11:11:17

21 certainly seemed like the right -- a good design 11:11:23

22 path for me. 11:11:27

23 Q. So you -- you said two things. The 11:11:29

24 material of the wires and the fluid mechanics of the 11:11:32

25 flow around or -- or that's changed because of the 11:11:36

1 wires; is that right?

11:11:39

2 A. It could be multiple things; surface finish
3 of the wires, the patient's own coagulability, the
4 ability of the blood to clot more easily. Multiple
5 things can affect even though these patients are
6 well heparinized.

11:11:42

11:11:45

11:11:58

11:12:02

11:12:08

7 Q. And one of those things that can increase
8 the chances of clotting are a change in -- in the
9 fluid mechanics; is that right?

11:12:09

11:12:11

11:12:14

10 MR. STOWELL: Objection. Misstates the
11 testimony.

11:12:16

11:12:17

12 THE WITNESS: I think in general for large
13 devices in the flow path, and I'm thinking also
14 about my experience with abdominal aortic aneurysm
15 devices, that having a more laminar fluid flow is
16 generally considered beneficial for implanting
17 devices.

11:12:33

11:12:35

11:12:38

11:12:45

11:12:58

11:13:01

18 By MR. HAMILTON:

11:13:13

19 Q. And when you say a more laminal -- laminar
20 flow is beneficial for devices, does that mean a
21 less laminar flow is more likely to form a thrombus
22 clot or a clot?

11:13:13

11:13:16

11:13:25

11:13:29

23 A. I think that can be a consequence of
24 disturbing flow -- normal flow patterns.

11:13:37

11:13:39

25 Q. And part of this disclosure set forth in

11:13:46

1 paragraph 18 is to minimize changes to -- withdraw
2 the question.

3 If you could turn to paragraph 53 of your
4 '910 supplemental declaration. Let me know when you
5 are ready for a question.

6 A. Okay.

7 Q. Do you see the phrase, "I observed many
8 intravascular medical procedures in which physicians
9 reinfused a patient's blood that had been collected
10 in a syringe?"

11 Do you see that?

12 A. Yes.

13 Q. What did you mean by "observed?"

14 A. That I have attended numerous procedures.
15 Here I'm thinking mostly about the MitraClip device
16 procedure that I attended dozens if not hundreds of
17 human cases.

18 Q. So you said mostly MitraClip -- are
19 there -- MitraClip cases. Are there any other you
20 can think of that you have observed in which
21 physicians reinfused a patient's blood that had been
22 collected in a syringe?

23 A. I think there have been. I can't remember
24 which procedures they might have been.

25 Q. When did you last work on the MitraClip?

1 A. 2012. 11:17:08

2 Q. When did you last observe one of these 11:17:11

3 procedures in wish -- in which physicians reinfused 11:17:14

4 a patient's blood that had been collected in a 11:17:18

5 syringe? 11:17:21

6 A. After 2012 I worked -- I continued to work 11:17:27

7 for Abbott but I was working in their business 11:17:29

8 development, venture capital side of the business, 11:17:34

9 but I think I still saw a few cases between 2015 and 11:17:41

10 2012. Most of the cases I'm referring to would have 11:17:46

11 been prior to 2012. 11:17:50

12 Q. When you say "observed," were you 11:17:54

13 physically present in the room where that physician 11:17:55

14 reinfused a patient's blood that had been collected 11:18:00

15 in a syringe? 11:18:03

16 A. Yes. And I will add that in the early days 11:18:04

17 I was frequently scrubbed in to the case and helping 11:18:07

18 the staff with preparing the devices and I was in 11:18:15

19 the sterile field with the physician while he was 11:18:21

20 doing the procedure acting as a proctor, especially 11:18:23

21 during the early -- early years. 11:18:29

22 Q. You used the term "many." How many? 11:18:32

23 A. How many what? 11:18:35

24 Q. In your sentence you said, "I observed many 11:18:37

25 intravascular medical procedures in which physicians 11:18:41

1 reinfused a patient's blood that had been collected 11:18:44
2 in a syringe." How many? 11:18:46

3 A. Before I said dozens or hundreds. I think 11:18:50
4 it was really hundreds. I scrubbed in to dozens, I 11:18:54
5 would say. 11:19:03

6 Q. So whether you scrubbed in or not, for 11:19:15
7 those hundreds you were present in the room where 11:19:17
8 this occurred? 11:19:19

9 A. Yes. 11:19:20

10 Q. And where did this occur? 11:19:22

11 A. In catheterization labs all over the 11:19:24
12 world -- Europe and the US. 11:19:28

13 Q. Did you -- have you ever reinfused a 11:19:52
14 patient's blood that had been collected in a 11:20:12
15 syringe? 11:20:14

16 A. No. Pigs, yes, not animals -- not 11:20:15
17 humans. 11:20:22

18 Q. When you say "physicians," who are these 11:20:23
19 physicians? 11:20:25

20 A. Generally these are interventional 11:20:28
21 cardiologists, although some cardiothoracic surgeons 11:20:33
22 also were trained and learned the procedure and 11:20:36
23 performed procedures usually in partnership with an 11:20:37
24 interventional cardiologist. 11:20:43

25 Q. Can you identify any of these physicians so 11:20:49

1	we can contact them?	11:20:52
2	A. Sure.	11:20:54
3	Q. Can you do that now?	11:20:55
4	A. Yes.	11:21:02
5	Q. Who would be one of these physicians?	11:21:05
6	A. Saibal, S-a-i-b-a-l, Kar, K-a-r.	11:21:09
7	Q. Where is Saibal Kar located?	11:21:19
8	A. He's at this point down in Orange County	11:21:22
9	somewhere. At the time he was at Cedars-Sinai in	11:21:24
10	Beverly Hills.	11:21:31
11	Q. And if -- if we asked for others, could you	11:21:31
12	identify others?	11:21:34
13	A. Yes.	11:21:35
14	Q. How much blood was reinfused?	11:21:44
15	A. They generally used a 60cc syringe. I'm	11:21:57
16	not sure that it was -- I'm not sure of the amount	11:22:04
17	but it was less than 60ccs is what the -- the lumen	11:22:07
18	of the guiding catheter would -- would contain.	11:22:14
19	Q. Would it have been less than 30ccs?	11:22:19
20	A. I don't know for sure.	11:22:23
21	Q. Could it have been less than 30ccs?	11:22:30
22	A. I'm not sure.	11:22:32
23	Q. So other than you believe a 60cc syringe	11:22:37
24	was used -- are you sure it was a 60cc syringe?	11:22:40
25	A. I could look in the IFU. I think we might	11:22:48

1	specify it in there.	11:22:52
2	Q. So as you sit here, are you sure it was a	11:22:53
3	60cc syringe?	11:22:56
4	A. I'm not sure if it was a 30 or a 60.	11:22:58
5	Different hospitals use different syringes.	11:23:04
6	Q. And whatever syringe was used, some lesser	11:23:07
7	amount was reinfused; is that correct?	11:23:09
8	A. Certainly if it was a 60cc syringe, less	11:23:14
9	than that amount of blood was typically aspirated	11:23:18
10	and then provided back to the patient.	11:23:22
11	Q. Why was that blood aspirated?	11:23:25
12	A. To assure that there was not air inside the	11:23:31
13	guiding catheter.	11:23:35
14	Q. Any other reason?	11:23:36
15	A. That was the clinical reason to do so.	11:23:45
16	Q. Are you aware of any other reason that that	11:23:47
17	blood was aspirated?	11:23:49
18	A. No. It was to be sure there was no air	11:23:55
19	that would then be injected into the patient at a	11:23:58
20	later step.	11:24:02
21	Q. Was it ever used to perform a	11:24:06
22	thrombectomy?	11:24:12
23	A. Was the guiding catheter ever used?	11:24:13
24	Q. These procedures that you observed, were	11:24:16
25	any of those procedures in which a patient's blood	11:24:17

1 that had been collected in a syringe came from 11:24:20
2 aspiration for a thrombectomy? 11:24:25

3 A. No. The procedure was not a thrombectomy 11:24:29
4 procedure. 11:24:32

5 Q. And was this something that would occur at 11:24:56
6 the beginning of a procedure involving the 11:24:59
7 MitraClip? 11:25:01

8 A. It was early on in the procedure. It's one 11:25:06
9 of the earlier steps where the guiding catheter and 11:25:08
10 dilator are inserted into the patient, the dilator 11:25:11
11 is removed and then aspiration of the guide catheter 11:25:14
12 occurred before proceeding to the next step. 11:25:22

13 Q. And how long after the physician would 11:25:32
14 aspirate blood out of the catheter was that blood 11:25:35
15 reinfused into a patient? 11:25:38

16 A. I would say almost immediately, as long as 11:25:42
17 time it took to disconnect the syringe and reconnect 11:25:46
18 it to the port that they were going to infuse it 11:26:01
19 into. 11:26:05

20 Q. Was that blood ever filtered before it was 11:26:26
21 reinfused? 11:26:30

22 A. No, I don't believe so. 11:26:31

23 Q. If you could turn to page 15, paragraph 32 11:27:22
24 of the '910 supplemental declaration. 11:27:26

25 A. Page 15? 11:27:40

1 Q. Page 15, yes, paragraph 32. I have some 11:27:41
2 questions about this figure on page 15. Let me know 11:28:15
3 when you're ready for questions. 11:28:19

4 A. Okay. 11:28:21

5 Q. How does the pump shown on page 15 generate 11:28:35
6 a negative pressure differential? 11:28:41

7 A. Well, it's described as a vacuum pump which 11:28:50
8 is connected to the reception canister 707, so a 11:28:55
9 vacuum pump creates a vacuum in that chamber. 11:29:02

10 Q. What is reception canister 707? 11:29:10

11 A. That is where the blood would be deposited 11:29:19
12 from the catheter. 11:29:31

13 Q. So for this reception canister, how is a 11:29:36
14 vacuum created in that reception canister? 11:29:40

15 A. By the vacuum pump. 11:29:44

16 Q. And is that via this tube labeled 705? 11:29:46

17 A. I would have to look at the patent to see 11:29:56
18 how they labeled 705. I didn't label it in here. 11:29:58
19 That does appear to be the means of connection to 11:30:02
20 the vacuum pump into the canister -- the means of 11:30:06
21 connection between the pump and the canister. 11:30:13

22 Q. Is canister 707 sealed? 11:30:21

23 A. Yes. 11:30:30

24 Q. So other than this connection that -- is it 11:30:32
25 705 and then the other connection to 706, canister 11:30:40

1	707 is sealed; correct?	11:30:53
2	A. It is because if it were not sealed, you	11:30:58
3	wouldn't be able to create a vacuum within the	11:31:00
4	canister.	11:31:04
5	Q. How does blood get from the patient to	11:31:37
6	canister 707 -- reception canister 707 -- excuse	11:31:44
7	me -- vacuum chamber. You've -- you've labeled it	11:31:50
8	reception canister but in quotes a vacuum chamber;	11:31:54
9	correct?	11:31:59
10	A. That's what it's labeled here, yes.	11:31:59
11	Q. And how does blood get from the patient to	11:32:01
12	that vacuum chamber?	11:32:04
13	A. Blood will flow through tubing 708 through	11:32:10
14	the rotating valve 711 through tube 706 and into the	11:32:20
15	vacuum chamber.	11:32:27
16	Q. What does rotating valve 711 do?	11:32:30
17	A. 711 is a rotating valve that may be closed	11:32:56
18	after the vacuum pump is turned on such that tube	11:32:58
19	708 is no longer exposed to the vacuum within the	11:33:02
20	canister 707.	11:33:05
21	Q. Does rotating valve 711 create a pulsing	11:33:13
22	vacuum?	11:33:22
23	A. As Brady says -- as I say on page 18,	11:33:27
24	"Brady then explains that the valve may be opened so	11:33:31
25	that a vacuum pulse may be delivered through the	11:33:34

1 tube 708 to aspirate the clot material."

11:33:38

2 Q. And once blood goes from the patient to
3 vacuum chamber 707, where does it go after that?

11:33:46

11:33:50

4 A. It depends what the physician wants to do
5 with it.

11:34:02

11:34:04

6 Q. Does it go through tube 705?

11:34:07

7 A. No.

11:34:13

8 Q. Can it go through tube 705?

11:34:20

9 A. It certainly would not be the intent. I
10 guess if they overfilled the canister and the port
11 was low enough into the canister, it's possible but
12 that would certainly not be the intent.

11:34:28

11:34:35

11:34:40

11:34:45

13 Q. Does vacuum pump 714 -- excuse me -- 714,
14 can that vacuum pump be used to move the blood out
15 of vacuum chamber 707?

11:34:58

11:35:09

11:35:15

16 A. I don't think that's the intent. The
17 intent is to create a air vacuum, let's say, within
18 the reception canister.

11:35:19

11:35:21

11:35:28

19 Q. If the pump -- vacuum pump 714 is turned on
20 and operating, would that apply a continuous
21 pressure differential to vacuum chamber 707?

11:35:56

11:36:00

11:36:05

22 A. Assuming the pump is on, the intent is to
23 create a vacuum in that chamber.

11:36:15

11:36:18

24 Q. So then would it be a fair summary to say
25 that the pump shown here on page 15 generally

11:36:55

11:36:59

1 operates by having a sealed vacuum chamber? 11:37:29

2 A. Certainly if it weren't sealed, you 11:37:37
3 wouldn't be able to create a significant vacuum that 11:37:39
4 the physician wants to use -- wants in order to 11:37:43
5 perform a thrombectomy procedure. 11:37:46

6 Q. And then if we look at the pump shown on 11:37:51
7 page 16, that operates from essentially the same 11:37:59
8 principle, correct, a sealed vacuum chamber? 11:38:03

9 A. Yes because you're using vacuum to -- it's 11:38:24
10 using pumps to create a vacuum in a chamber. 11:38:27

11 Q. And that -- just like the pump we discussed 11:38:31
12 on page 15, this one on page 16 creates a vacuum and 11:38:36
13 in that sealed vacuum chamber -- withdraw the 11:38:46
14 question. 11:38:50

15 Is there an outlet for blood in the vacuum 11:38:57
16 chamber on figure 19? 11:39:00

17 A. They're not showing an outlet connected to 11:39:10
18 the chamber that I can see in this rough hand sketch 11:39:15
19 from the patent. 11:39:23

20 Q. And for the pump -- vacuum pump 502 to 11:39:24
21 apply a vacuum to the aspiration catheter, there 11:39:34
22 couldn't be an outlet for vacuum chamber -- for 11:39:44
23 blood in vacuum chamber -- in the vacuum chamber in 11:39:48
24 figure 19; correct? 11:39:52

25 A. Well there couldn't be an open connector. 11:39:54

1 It would need to be a closed system to create a 11:39:56
2 vacuum. 11:40:00

3 Q. And is that the same -- I just want to -- 11:40:00
4 let's see. 11:40:09

5 We have got a couple different pumps here. 11:40:10
6 So you got another one on page 19. Does that pump 11:40:11
7 operate by the same principle of a sealed vacuum 11:40:15
8 chamber? 11:40:18

9 A. Yes, I believe the pumps that we show from 11:40:22
10 Pons, Penumbra, and Medela all function similarly in 11:40:26
11 creating a vacuum in a chamber in order to perform a 11:40:36
12 thrombectomy. 11:40:46

13 Q. Do you have any personal experience with a 11:40:47
14 Medela pump? 11:40:49

15 A. No. 11:40:51

16 Q. Did you identify the Medela pump to include 11:40:54
17 in your declaration? 11:40:57

18 A. No. I think counsel provided this 11:40:59
19 example. 11:41:03

20 Q. What about the other pumps identified in 11:41:55
21 your supplemental declaration, did you identify any 11:41:58
22 of those pumps or did counsel provide those to 11:42:01
23 you? 11:42:03

24 A. Yeah, I think the commercial pumps shown, 11:42:13
25 Pons, Penumbra, Medela, I believe these were 11:42:18

1 provided by counsel.

11:42:22

2 Q. So just to clarify, you had said Pons is a
3 commercial pump but Pons is a patent; correct?

11:42:27

11:42:31

4 A. I seem to remember it's assigned to
5 Penumbra so I'm assuming it's led into their pump
6 but I'm not sure.

11:42:38

11:42:42

11:42:47

7 Q. Do you have any personal experience with
8 any of the pumps set forth in your supplemental
9 declaration -- '910 supplemental declaration?

11:42:58

11:43:00

11:43:03

10 A. I have not used any of these pumps -- these
11 specific pumps, no.

11:43:09

11:43:12

12 Q. Have you ever seen any of these in
13 person?

11:43:14

11:43:18

14 A. No.

11:43:18

15 Q. Other than the documents supplied with your
16 declaration, are you aware of how these pumps
17 operate or what they're used for?

11:43:18

11:43:22

11:43:25

18 MR. STOWELL: Objection. Vague.

11:43:27

19 THE WITNESS: I'm aware of how they operate
20 and what they're used for.

11:43:31

11:43:33

21 By MR. HAMILTON:

11:43:34

22 Q. And is that based on the documents supplied
23 with your declaration?

11:43:34

11:43:38

24 A. Yes.

11:43:49

25 Q. Is it based on anything else?

11:43:50

1 A. Well I did do a Google search recently to 11:43:56
2 find out what type of vacuum pump Penumbra MAX uses 11:44:00
3 inside its housing. Also the Medela pump. 11:44:07
4 Q. And do you know the answer to that 11:44:17
5 question? 11:44:19
6 A. I can't remember which is which but one of 11:44:22
7 them is a variable vein type vacuum pump and one is 11:44:25
8 a piston type pump. 11:44:30
9 Q. I'm going to hand you what's been marked as 11:44:47
10 Exhibit 1039. 11:44:50
11 Do you recognize Exhibit 1039? 11:45:06
12 A. Yes. 11:45:09
13 Q. And what is Exhibit 1039? 11:45:17
14 A. It's a brochure for the AXS, A-X-S, 11:45:29
15 Universal Aspiration Set. I can't read what the 11:45:41
16 date -- copyright date would be. 11:45:57
17 Q. So in looking at your declaration, the '910 11:46:02
18 supplemental declaration, paragraph 40, with respect 11:46:06
19 to this Medela pump, the only document you cite is 11:46:09
20 Exhibit 1039. 11:46:15
21 Do you see that? 11:46:18
22 A. Yes. 11:46:20
23 Q. In coming to your understanding of how the 11:46:21
24 Medela pump works, did you rely on any other 11:46:24
25 information beyond Exhibit 1039? 11:46:28

1	A. No.	11:46:34
2	Q. Focusing on the Penumbra Pump MAX that's on	11:48:42
3	page 21 of your declaration, is that pump used to	11:48:45
4	return blood to a patient during an aspiration	11:48:58
5	thrombectomy?	11:49:03
6	A. Yeah. My understanding is that pump is	11:49:27
7	used to evacuate the canister to perform a	11:49:29
8	thrombectomy procedure, not to reinfuse -- the same	11:49:35
9	pump isn't necessarily -- isn't used to reinfuse	11:49:40
10	blood to the patient.	11:49:44
11	Q. Do you know if blood that is aspirated from	11:49:50
12	a patient using the Penumbra Pump MAX is reinfused	11:49:52
13	into that patient?	11:49:59
14	A. I think it depends on the physician and	11:50:05
15	what they want to do and how much blood might be	11:50:06
16	removed during the procedure.	11:50:08
17	Q. Is the Penumbra Pump MAX designed so that	11:50:10
18	blood can be reinfused into a patient from the	11:50:14
19	collection canister found in that pump?	11:50:17
20	A. I'm sure there is a means to remove blood	11:50:23
21	from a collection canister if the patient -- if the	11:50:26
22	physician wanted to reinfuse it to the patient.	11:50:29
23	Q. And is it your understanding that a	11:50:31
24	physician would reinfuse blood from the Penumbra	11:50:33
25	Pump MAX that was collected during an aspiration	11:50:39

1 thrombectomy?

11:50:44

2 A. I think it depends on the physician and the
3 procedure and how much blood may have been collected
4 in the canister.

11:50:45

11:50:47

11:50:50

5 Q. Are you aware of any physician ever
6 reinfusing blood that was collected during an
7 aspiration thrombectomy with a Penumbra Pump MAX?

11:50:51

11:50:54

11:50:59

8 A. I haven't personally witnessed a procedure
9 with this pump, no.

11:51:04

11:51:06

10 Q. Are you aware of any procedure that's ever
11 been performed with this pump?

11:51:10

11:51:12

12 A. I presume it is a commercially -- it was a
13 commercially available pump at the time so I'm
14 presuming that it's been used many times
15 commercially.

11:51:26

11:51:29

11:51:33

11:51:35

16 Q. But you're not aware of any instance where
17 it's actually been used to perform a thrombectomy;
18 correct?

11:51:35

11:51:37

11:51:40

19 A. I haven't observed it myself, no.

11:51:42

20 Q. Are you aware of any instance where it's
21 actually been used for a thrombectomy?

11:51:44

11:51:46

22 A. I believe that's the indication for this
23 pump is to use for mechanic -- for aspiration
24 thrombectomy.

11:51:52

11:51:54

11:52:01

25 Q. So you're assuming it's been used for its

11:52:02

1 indication; is that correct? 11:52:05

2 A. I'm assuming that it's used for its 11:52:07

3 indication as it says on page 22, "Pons describes 11:52:10

4 the prior art Penumbra mechanical thrombectomy 11:52:19

5 system which is a fully integrated system designed 11:52:22

6 specifically for mechanical thrombectomy by 11:52:25

7 aspiration." 11:52:28

8 Q. And beyond that statement, are you aware of 11:52:29

9 any actual use of this pump in a mechanical 11:52:32

10 thrombectomy by aspiration? 11:52:36

11 A. I have not witnessed any myself. 11:52:39

12 Q. Are you aware of any? 11:52:40

13 A. I'm -- I think I've answered the 11:52:44

14 question. 11:52:47

15 Q. And is that answer no? 11:52:50

16 A. I haven't witnessed any myself. I assume 11:52:52

17 that it has been used commercially. 11:52:55

18 Q. Are you aware of any instance in which 11:53:06

19 blood collected during a mechanical thrombectomy by 11:53:08

20 aspiration using the Penumbra pump was returned to a 11:53:14

21 patient? 11:53:19

22 A. I have not witnessed that, no. 11:53:25

23 Q. Do you believe a -- a physician would do 11:53:26

24 that? 11:53:28

25 A. I believe a physician would do that if it 11:53:31

1 was a significant amount of blood and it made sense 11:53:33
2 for the patient to give it back. 11:53:38

3 Q. Do you believe the Penumbra Pump MAX is 11:53:49
4 designed so that a physician can reinfuse blood 11:53:51
5 that's been collected during a mechanical 11:53:54
6 thrombectomy by aspiration using that pump? 11:53:57

7 A. Can you repeat the question. 11:54:00

8 Q. Do you believe the Penumbra Pump MAX is 11:54:02
9 designed so that a physician can reinfuse blood that 11:54:04
10 has been collected during a mechanical thrombectomy 11:54:08
11 by aspiration using the Penumbra Pump MAX? 11:54:12

12 A. I certainly believe that it would be 11:54:23
13 designed to be able to remove the blood from the 11:54:26
14 canister, collected in a syringe, and given back to 11:54:30
15 the patient. 11:54:36

16 Q. And that's your understanding in forming 11:54:36
17 your opinions in your -- in this matter -- in these 11:54:38
18 matters? 11:54:43

19 A. I certainly think there probably would be 11:54:49
20 connectors such that the physician could remove 11:54:52
21 blood into a syringe and provide it back to the 11:54:56
22 patient. 11:55:03

23 Q. Are you assuming that there's connectors or 11:55:03
24 are you aware of connectors actually existing to do 11:55:08
25 that? 11:55:13

1 A. I'm assuming that that would be possible
2 with this system.

3 Q. And that was your understanding in forming
4 your opinions in these matters; correct?

5 A. Well that aspect I don't think was a
6 significant feature of this declaration. We provide
7 this example to show that a person of skill in the
8 art would have had several options to choose from
9 when choosing a vacuum pump.

10 MR. STOWELL: We have about another hour if
11 you want.

12 MR. HAMILTON: Do you want a break? It's
13 noon. I'm happy to break for lunch.

14 THE WITNESS: Yeah, whenever is good stop
15 -- stopping time.

16 MR. HAMILTON: Yeah, why don't we -- yeah,
17 don't we take a break.

18 THE VIDEOGRAPHER: We are going off the
19 record at 11:57.

20 (Lunch recess.)

21 THE VIDEOGRAPHER: We are back on the
22 record at 12:43.

23 By MR. HAMILTON:

24 Q. Mr. Thornton, do you understand you're
25 still under oath?

11:55:14

11:55:15

11:55:20

11:55:22

11:55:32

11:55:34

11:55:45

11:55:48

11:55:54

11:56:59

11:57:01

11:57:01

11:57:04

11:57:06

11:57:11

11:57:12

11:57:15

11:57:16

11:57:17

12:42:40

12:43:07

12:43:07

12:43:13

12:43:13

12:43:14

1	A. Yes.	12:43:15
2	Q. Did you communicate with anyone in any way	12:43:16
3	regarding the subject of these matters during the	12:43:18
4	break?	12:43:21
5	A. No.	12:43:22
6	Q. Did you review any documents during the	12:43:23
7	break?	12:43:25
8	A. No.	12:43:25
9	Q. If you go to paragraph -- let's look at	12:43:47
10	your '910 supplemental declaration, paragraph 29,	12:43:50
11	and I'm going to ask you a question about the top of	12:43:56
12	page 14 which is at the end of paragraph 29. Let me	12:44:01
13	know when you're ready for the question.	12:44:29
14	A. Okay.	12:44:52
15	Q. Do you see the phrase "cardiopulmonary	12:44:53
16	bypass pumps" on the top of page 14?	12:44:57
17	A. Yes.	12:45:00
18	Q. Do you understand what a cardiopulmonary	12:45:02
19	bypass pump is?	12:45:05
20	A. Yes.	12:45:07
21	Q. Do you generally understand how those types	12:45:08
22	of pumps operate?	12:45:10
23	A. Generally.	12:45:13
24	Q. What is a cardiopulmonary bypass pump?	12:45:17
25	A. It's a pump used to perform cardiopulmonary	12:45:22

1 bypass during open heart surgery. 12:45:26

2 Q. Does that pump allow the circulation of 12:45:36
3 blood? 12:45:39

4 MR. STOWELL: Objection. Vague. 12:45:42

5 THE WITNESS: The pumps are designed to 12:45:51
6 take blood from the venous circulation, pump it 12:45:57
7 through an oxygenator, and return it back to the 12:46:03
8 patient. 12:46:08

9 By MR. HAMILTON: 12:46:13

10 Q. Do those pumps generally have an inlet 12:46:13
11 port? 12:46:16

12 A. Yes. 12:46:21

13 Q. And is that where those pumps take blood? 12:46:22

14 A. The inlet port is connected to the return 12:46:32
15 cannula, the -- the venous cannula that is inserted 12:46:37
16 in the patient. 12:46:40

17 Q. So does the inlet port receive blood or 12:46:42
18 expel blood? 12:46:47

19 A. Receives blood from the venous cannula. 12:46:49

20 Q. And would the cardiopulmonary bypass pump 12:46:53
21 create negative pressure at the inlet port? 12:46:59

22 A. They do provide negative pressure or vacuum 12:47:07
23 in order to pull the blood into the pump. 12:47:09

24 Q. And is that negative pressure provided at 12:47:13
25 the inlet port? 12:47:16

1 A. Sure. It creates a negative pressure at 12:47:29
2 the inlet port which is attached to the cannula in 12:47:32
3 the patient. 12:47:35

4 Q. And would a cardiopulmonary bypass pump 12:47:36
5 have a -- a discharge port? 12:47:39

6 A. Yes. 12:47:42

7 Q. And would the cardiopulmonary bypass pump 12:47:44
8 create positive pressure at the discharge pump? 12:47:49

9 A. Yes. 12:47:52

10 Q. For catheters used for aspirating, 12:48:11
11 generally speaking, would a larger catheter aspirate 12:48:16
12 more blood than a smaller catheter in terms of 12:48:21
13 French size? 12:48:24

14 A. Given the same vacuum applied to the 12:48:29
15 catheter, yes. 12:48:32

16 Q. Is there a French size you would consider 12:48:41
17 small for an aspiration catheter? 12:48:44

18 A. It depends on the application, the location 12:48:50
19 being aspirated. 12:48:55

20 Q. So it depends on the context to determine 12:49:07
21 whether a catheter is large or small for aspiration; 12:49:10
22 is that right? 12:49:16

23 A. Large and small and a wide range of 12:49:19
24 definitions. 12:49:23

25 Q. So for treating a clot in the cerebral 12:49:25

1	vasculature, would a 8 French catheter be considered	12:49:30
2	large or small?	12:49:34
3	A. I don't know. I think there are ones that	12:49:38
4	are smaller and larger.	12:49:40
5	Q. What about treating a clot in the pulmonary	12:49:57
6	system, would a 8 French catheter be considered	12:50:02
7	large or small?	12:50:05
8	A. I think typically they would use a larger	12:50:08
9	catheter size than an 8 French to treat most	12:50:12
10	pulmonary embolisms.	12:50:19
11	Q. How much larger?	12:50:22
12	A. I think some of these patents discuss sizes	12:50:28
13	up to maybe 22 French. So there's a wide range that	12:50:31
14	could be used I believe.	12:50:38
15	Q. I'm going to hand you what has been	12:51:43
16	previously marked Exhibit 1068 in IPR2025-01025.	12:51:45
17	Do you recognize Exhibit 1068?	12:52:00
18	A. Yes.	12:52:03
19	Q. What is Exhibit 1068?	12:52:05
20	A. It's a brochure or ordering -- ordering	12:52:16
21	information for the Penumbra MAX pump.	12:52:20
22	Q. And is this the same Penumbra Pump MAX	12:52:25
23	referenced in paragraph 38 of your '910 supplemental	12:52:30
24	declaration?	12:52:35
25	A. Yes. Certainly the image looks the same as	12:52:49

1	what we have on page 21.	12:52:52
2	Q. And, in fact, your declaration in the first	12:53:11
3	instance is the 1068?	12:53:15
4	A. Yes.	12:53:19
5	Q. Has the Penumbra Pump MAX; correct?	12:53:19
6	A. Yes.	12:53:24
7	Q. Do you see on page 1 of Exhibit 1068 the	12:53:33
8	notation on the right saying, "Large 0.088 inch ID	12:53:40
9	reinforced tubing for efficient flow?"	12:53:48
10	A. Yes.	12:53:50
11	Q. Do you have an understanding for what .088	12:54:02
12	inch ID is in French size?	12:54:10
13	A. If you divide by .01312, you can calculate	12:54:16
14	French size.	12:54:21
15	Q. And what is the French size for a .088 inch	12:54:26
16	ID reinforced tubing?	12:54:32
17	A. I don't want to do the math in my head	12:54:34
18	right now.	12:54:36
19	Q. Why don't I -- I'll -- I'll do it for you	12:54:38
20	and you tell me if this sounds about right.	12:54:41
21	So did you say you divide that number by --	12:54:49
22	A. .01312, I believe.	12:54:52
23	Q. 6.7? Does that sound about right?	12:54:59
24	A. Seems pretty close. I notice on the next	12:55:04
25	page where they list an inner diameter of .088	12:55:07

1 inches they list a distal OD of 8 French so it seems 12:55:14
2 reasonable to have something close to 7 French 12:55:18
3 inside diameter. 12:55:23

4 Q. What's the largest French size listed on 12:55:24
5 the second page? 12:55:27

6 A. I think that 8 French example that I see on 12:55:34
7 the bottom half of the page. 12:55:39

8 Q. And that is the external diameter; 12:55:42
9 correct? 12:55:44

10 A. Yes. It says distal OD. 12:55:45

11 Q. So the internal diameter would be less than 12:55:47
12 that and then 7 is not a -- not a bad estimate of 12:55:50
13 what that probably is; is that right? 12:55:53

14 A. Yes. It's .088 inches. 12:55:56

15 Q. And it can't be larger than 8 French; 12:55:59
16 right? 12:56:01

17 A. Correct. 12:56:02

18 Q. And what's the smallest French shown on 12:56:03
19 that page 2? 12:56:08

20 A. There is only one sheath -- there's only 12:57:00
21 one sheath size listed for the long sheath is .088 12:57:03
22 inner diameter. They show a select catheter at .04 12:57:09
23 inches inside diameter. Microcatheter lists even 12:57:14
24 smaller, .025 inner diameter. That's the smallest 12:57:26
25 number I see. 12:57:35

1	Q.	So is it fair to say that this document	12:57:36
2		shows catheters with the French size between 3 and 8	12:57:40
3		approximately?	12:57:48
4	A.	Well, the microcatheter goes within the	12:57:48
5		sheath but, yeah, it's 2.6 French OD up to 8 French	12:57:55
6		OD for the long sheaths.	12:58:01
7	Q.	I'm going to hand you another document.	12:58:51
8		This one has been marked Exhibit 1020.	12:58:53
9		Do you recognize Exhibit 1020?	12:59:06
10	A.	Yes.	12:59:18
11	Q.	Is this the Brady reference referred to in	12:59:19
12		paragraph 31 of your '910 supplemental	12:59:24
13		declaration?	12:59:32
14	A.	Yes.	12:59:32
15	Q.	If you would turn to page 9 of Exhibit	12:59:49
16		1020. If you go down to line 25.	12:59:53
17		Do you see reference to a large aspiration	13:00:13
18		lumen?	13:00:15
19	A.	Yes.	13:00:27
20	Q.	And Brady discloses that that large	13:00:28
21		aspiration lumen has a cross-sectional area greater	13:00:33
22		equivalent to .030 diameter.	13:00:37
23		Do you see that?	13:00:41
24	A.	Yes.	13:00:42
25	Q.	Is that about 2.3 French?	13:00:45

1	A.	Something less than 2.6 French is what it	13:01:33
2		would --	13:01:38
3	Q.	And then --	13:01:39
4	A.	2.4, 2.5 French probably.	13:01:39
5	Q.	Thank you. Two lines down, line 28, do you	13:01:42
6		see .040 diameter lumen?	13:01:46
7	A.	Yes.	13:01:49
8	Q.	Is that about 3 French?	13:01:49
9	A.	Yeah. I seem to remember 3 French is	13:02:04
10		around 039 so pretty close, yeah.	13:02:07
11	Q.	I'm going to hand you what's marked Exhibit	13:02:25
12		1038.	13:02:31
13		Do you recognize Exhibit 1038?	13:03:00
14	A.	Yes.	13:03:11
15	Q.	What is Exhibit 1038?	13:03:12
16	A.	It's a notice from the FDA to Penumbra in	13:03:43
17		March of 2018 regarding their 510(k) review for the	13:03:47
18		Indigo aspiration system Penumbra engine pump and	13:04:01
19		canister.	13:04:06
20	Q.	In that context -- in the context of	13:04:10
21		Exhibit 1038, do you understand what predicate	13:04:12
22		device means?	13:04:16
23	A.	Yes.	13:04:21
24	Q.	What does predicate device mean in that	13:04:21
25		context?	13:04:24

1 A. On their FDA regulations for a 510(k)
2 pre-market notification, you need to show
3 substantial equivalence to a existing approved
4 device.

5 Q. So if you turn to page 2 of 8. Labeled 2
6 of 8. I don't believe it's the second page of the
7 document but at the bottom it's labeled 2 of 8.

8 Do you see the heading "Predicate
9 Comparison?"

10 A. Yes.

11 Q. And if you go down to "Aspiration Pump."

12 What is the predicate device in this
13 document?

14 A. Penumbra Pump MAX and canister.

15 Q. And is that the Penumbra Pump MAX
16 referenced in paragraph 38 of your '910 supplemental
17 declaration?

18 A. It has the same name. I'm not completely
19 sure if they had other iterations along the years.
20 So I'm not sure.

21 Q. Do you have any reason to doubt if it's the
22 same or to know one way or the other?

23 A. Yeah, I don't know. They would have to
24 provide catalog numbers and more specifics to be
25 sure but it certainly could be the same -- same

1 device.

13:06:43

2 Q. And you see the second and third column,
3 it's titled "Predicate Device" and "Subject Device?"

13:06:44

13:06:46

4 A. Yes.

13:06:51

5 Q. Is that comparing the predicate device to
6 the new or updated device in terms of if they're the
7 same or different?

13:06:52

13:06:56

13:07:00

8 A. Yeah, that's how FDA approves a 510(k)
9 application.

13:07:08

13:07:16

10 Q. So with respect to say a particular
11 feature, and let's just say -- take the aspirational
12 pump and frequency.

13:07:16

13:07:18

13:07:22

13 Do you see that?

13:07:25

14 A. Yes.

13:07:30

15 Q. For frequency, the FDA has determined that
16 the Penumbra Pump MAX and canister is the same as
17 the Penumbra engine pump -- excuse me -- engine pump
18 and canister; is that right?

13:07:31

13:07:35

13:07:38

13:07:41

19 A. It says "same," yes.

13:07:43

20 Q. And what does that mean, "same?"

13:07:44

21 A. That it's substantially equivalent in FDA
22 language.

13:07:51

13:07:54

23 Q. So it would operate essentially in the same
24 way?

13:07:55

13:07:57

25 A. It meets FDA's requirements for substantial

13:08:00

1	equivalence.	13:08:04
2	Q. And what are the requirements for	13:08:05
3	substantial equivalence?	13:08:08
4	A. There's a big long document of 510(k)	13:08:11
5	regulations that are shown there on page 1 of 8 that	13:08:15
6	would expand on those requirements and	13:08:19
7	definitions.	13:08:25
8	Q. So let's look at the next row,	13:08:25
9	"Sterilization."	13:08:30
10	Do you see that?	13:08:31
11	A. Yes.	13:08:32
12	Q. For the Penumbra Pump MAX and canister it	13:08:33
13	says, "not sterile."	13:08:35
14	Do you understand what that means?	13:08:37
15	A. Yes.	13:08:38
16	Q. What does that mean?	13:08:38
17	A. That it's provided in the non-sterile	13:08:40
18	state.	13:08:43
19	Q. And the Penumbra engine pump and canister	13:08:46
20	it says "same;" correct?	13:08:49
21	A. Yes.	13:08:52
22	Q. So for the state of the Penumbra engine	13:08:52
23	pump and canister, that would also be non-sterile	13:08:55
24	just like the Penumbra Pump MAX and canister;	13:08:58
25	correct?	13:09:03

1	A. Yes.	13:09:03
2	Q. If the Penumbra Pump MAX and canister are	13:09:26
3	non-sterile, would a person of ordinary skill in the	13:09:29
4	art reintroduce blood into a patient that's been	13:09:32
5	collected by that canister?	13:09:36
6	A. Not if the blood -- not if it's not	13:10:10
7	sterile.	13:10:13
8	Q. When using a catheter for aspirating in a	13:10:48
9	thrombectomy procedure, is it desirable for that	13:10:53
10	catheter to clog?	13:10:57
11	A. No.	13:11:01
12	Q. Would one skilled in the art design a	13:11:02
13	device so that the catheter clogs or -- or increases	13:11:05
14	the chance -- the chances that the catheter clogs?	13:11:09
15	A. That wouldn't be the design intent, no.	13:11:13
16	Q. It would be the opposite, right, you would	13:11:16
17	try to design a device that doesn't clog; correct?	13:11:17
18	A. Yes. But depending on the size of the	13:11:25
19	clot, it not infrequently happens and other	13:11:27
20	maneuvers have to be performed.	13:11:32
21	MR. HAMILTON: All right. Well, thank you	13:11:38
22	for your time. I have no further questions.	13:11:39
23	MR. STOWELL: I don't have any questions	13:11:41
24	either.	13:11:43
25	THE VIDEOGRAPHER: All right. This marks	13:11:44

1 the end of the deposition of Troy Lane Thornton. We
2 are going off the record at 13:11.

13:11:45

13:11:48

3 (Proceedings concluded.)

4 ---o0o---

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

CERTIFICATE OF STENOGRAPHIC REPORTER

I, BURGUNDY B. RYAN, a Certified Shorthand Reporter, hereby certify that the witness in the foregoing deposition,

TROY LANE THORNTON, was by me duly sworn to tell the truth, the whole truth, and nothing but the truth, in the within-entitled cause; that said deposition was taken at the time and place therein named; that the testimony of said witness was stenographically reported by me, a disinterested person, and was thereafter transcribed into typewriting.

I further certify that I am not of counsel or attorney for either or any of the parties to said deposition, nor in any way interested in the outcome of the cause named in said caption.

DATED: Friday, July 3, 2026.



Burgundy B. Ryan, CSR No. 11373, RPR

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

85

A			
a-x-s	acute	along	answered
65:14	34:17, 34:18	79:19	14:17, 22:2,
abbott	add	already	22:10, 68:13
54:7	11:23, 54:16	47:9, 47:23,	anticipated
abdominal	additional	48:5, 48:12,	24:12
21:11, 39:12,	12:25	48:20, 49:9	anticoagulants
39:19, 52:14	adhesion	also	17:3
ability	46:23	2:21, 37:15,	antiplatelet
41:15, 52:4	advance	39:10, 42:24,	17:4
able	29:14	50:7, 52:13,	any
35:14, 35:16,	advanced	55:22, 65:3,	7:2, 7:6, 9:4,
35:17, 35:18,	44:6	81:23	9:24, 10:9,
36:19, 37:5,	adverse	alternative	11:3, 11:14,
37:12, 60:3,	24:9, 24:12,	34:12	11:16, 11:18,
62:3, 69:13	24:25, 25:11	although	11:21, 12:9,
about	affect	55:21	12:11, 12:14,
16:4, 23:15,	52:5	among	12:17, 12:25,
28:3, 28:6,	after	41:10	14:1, 16:2,
30:8, 30:21,	24:22, 32:21,	amount	16:8, 16:12,
39:23, 41:23,	37:1, 41:3,	56:16, 57:7,	19:11, 20:4,
45:5, 52:14,	51:12, 54:6,	57:9, 69:1	20:24, 25:10,
53:15, 59:2,	58:13, 60:18,	anesthesia	29:23, 31:10,
63:20, 70:10,	61:3	24:23	31:14, 31:16,
71:11, 74:5,	again	aneurysm	31:21, 32:7,
75:20, 75:23,	36:9	21:12, 52:14	34:4, 35:22,
77:25, 78:8	air	aneurysms	45:23, 46:2,
account	57:12, 57:18,	39:13, 39:20	50:10, 53:19,
23:4, 24:9	61:17	angeles	55:25, 57:14,
accumulation	all	2:17	57:16, 57:25,
34:20, 46:23	10:18, 18:5,	angioplasty	63:13, 63:21,
accumulative	18:22, 24:24,	21:11, 41:22,	64:7, 64:8,
47:5	25:2, 31:2,	42:25, 43:4,	64:10, 64:12,
achieving	38:20, 38:21,	43:6	65:24, 67:5,
23:8	43:18, 49:12,	animal	67:10, 67:16,
act	50:8, 55:11,	34:17, 34:18,	67:20, 68:9,
16:18	63:10, 82:21,	34:19, 37:16,	68:11, 68:12,
acting	82:25	37:22	68:16, 68:18,
54:20	allergic	animals	71:2, 71:6,
actual	25:15, 26:16,	20:2, 55:16	79:21, 82:23,
68:9	26:18, 26:25,	another	84:16, 84:17
actually	27:3, 27:6,	30:19, 36:13,	anyone
43:25, 67:17,	27:24, 27:25	37:25, 44:5,	45:23, 71:2
67:21, 69:24	allergist	63:6, 70:10,	anything
actuate	28:2	77:7	64:25
35:15	allow	answer	aortic
actuation	72:2	3:3, 22:5,	21:11, 39:12,
37:9	almost	22:17, 33:3,	39:20, 52:14
	38:21, 58:16	65:4, 68:15	appeal
			1:3, 5:16

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

86

appear 59:19 appeared 5:7 application 19:10, 73:18, 80:9 applications 41:7, 42:2 applied 73:14 apply 61:20, 62:21 appropriately 19:10, 35:15, 37:12 approved 38:19, 79:3 approves 80:8 approximately 77:3 area 77:21 areas 34:19 around 36:1, 51:20, 51:25, 78:10 arrhythmias 25:15, 28:3, 28:4 art 9:18, 9:20, 10:14, 11:4, 11:11, 12:1, 12:6, 12:20, 16:20, 16:21, 17:25, 21:16, 51:5, 51:10, 68:4, 70:8, 82:4, 82:12 article 38:2, 38:13 ashurst 2:13 asked 14:17, 22:1,	22:9, 56:11 aspect 34:5, 70:5 aspects 35:13 aspirate 58:14, 61:1, 73:11 aspirated 57:9, 57:11, 57:17, 66:11, 73:19 aspirating 32:21, 73:10, 82:8 aspiration 15:1, 16:4, 30:12, 30:22, 31:10, 31:14, 31:21, 32:1, 32:8, 32:12, 32:18, 32:20, 32:23, 32:25, 33:6, 58:2, 58:11, 62:21, 65:15, 66:4, 66:25, 67:7, 67:23, 68:7, 68:10, 68:20, 69:6, 69:11, 73:17, 73:21, 77:17, 77:21, 78:18, 79:11 aspirational 16:8, 31:4, 80:11 asset 38:9 assigned 64:4 assist 21:10 associated 35:12 assume 9:7, 68:16 assuming 61:22, 64:5,	67:25, 68:2, 69:23, 70:1 assure 57:12 astor 2:22, 5:21 atrial 25:15, 25:16, 28:6, 28:7 attached 73:2 attachment 26:11 attempted 26:24 attended 53:14, 53:16 attorney 84:16 author 37:15, 38:6, 38:8, 38:11, 38:12, 38:14, 38:24, 39:1, 39:4, 39:8, 40:13 authors 37:21 av 25:16 available 67:13 avoid 8:14 avoiding 48:23 aware 9:24, 10:8, 16:12, 57:16, 64:16, 64:19, 67:5, 67:10, 67:16, 67:20, 68:8, 68:12, 68:18, 69:24 axs 65:14 B back 6:24, 17:17,	21:25, 22:6, 33:9, 33:12, 38:16, 45:13, 45:17, 57:10, 69:2, 69:14, 69:21, 70:21, 72:7 bad 76:12 balloon 43:6 based 20:10, 24:6, 39:20, 64:22, 64:25 bear 2:4, 5:4 because 23:20, 27:8, 31:9, 38:5, 44:11, 50:3, 50:12, 51:16, 51:25, 60:2, 62:9 been 5:10, 6:20, 18:19, 23:22, 38:15, 40:6, 45:5, 53:9, 53:21, 53:23, 53:24, 54:4, 54:11, 54:14, 55:1, 55:14, 56:19, 56:21, 58:1, 65:9, 67:3, 67:11, 67:14, 67:17, 67:21, 67:25, 68:17, 69:5, 69:10, 74:15, 77:8, 82:4 before 1:3, 5:5, 5:16, 20:2, 33:11, 36:25, 43:12, 55:3, 58:12, 58:20 beginning 58:6
---	---	---	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

87

begins 5:12 behalf 2:3, 2:12, 5:9, 6:8 being 24:23, 32:11, 50:23, 73:19 believe 7:14, 10:2, 10:3, 14:6, 14:9, 21:3, 21:7, 21:18, 21:20, 21:23, 22:7, 22:15, 23:20, 27:5, 34:3, 39:3, 42:14, 43:3, 56:23, 58:22, 63:9, 63:25, 67:22, 68:23, 68:25, 69:3, 69:8, 69:12, 74:14, 75:22, 79:6 belly 39:21 bench 20:2, 34:22 beneficial 52:16, 52:20 besides 12:17, 32:9 better 49:8 between 9:24, 10:9, 13:22, 14:1, 14:14, 15:19, 54:9, 59:21, 77:2 beverly 56:10 beyond 12:15, 65:25, 68:8 big 81:4	bill 46:5 biocompatible 18:24, 26:20 bit 30:13 bleeding 25:17 blood 13:12, 18:5, 18:6, 18:23, 19:1, 19:17, 19:20, 21:10, 31:23, 32:20, 33:8, 33:11, 35:4, 36:12, 36:21, 36:23, 37:4, 37:7, 37:9, 40:23, 46:20, 47:20, 49:2, 49:4, 49:13, 49:14, 49:16, 49:20, 49:21, 49:22, 49:25, 50:1, 50:2, 50:18, 50:23, 51:3, 51:6, 51:12, 51:16, 52:4, 53:9, 53:21, 54:4, 54:14, 55:1, 55:14, 56:14, 57:9, 57:11, 57:17, 57:25, 58:14, 58:20, 59:11, 60:5, 60:11, 60:13, 61:2, 61:14, 62:15, 62:23, 66:4, 66:10, 66:11, 66:15, 66:18, 66:20, 66:24, 67:3, 67:6, 68:19, 69:1, 69:4, 69:9, 69:13, 69:21, 72:3, 72:6,	72:13, 72:17, 72:18, 72:19, 72:23, 73:12, 82:4, 82:6 board 1:3, 5:17 bold 46:17 both 13:24, 41:4 bottom 8:7, 76:7, 79:7 brady 60:23, 60:24, 77:11, 77:20 break 45:9, 45:12, 45:24, 46:3, 46:13, 70:12, 70:13, 70:17, 71:4, 71:7 brochure 65:14, 74:20 brooke 6:11, 6:14 build 48:16 buildup 34:13, 48:23, 51:10, 51:15 bullet 28:25, 29:1, 39:24, 46:15 bunch 51:12 burgundy 1:33, 5:5, 6:11, 6:14, 84:4, 84:23 bush 5:4, 6:1 business 54:7, 54:8 bypass 21:10, 71:16, 71:19, 71:24, 72:1, 72:20, 73:4, 73:7	C cables 37:10 calculate 75:13 california 1:24, 2:8, 2:17, 5:5, 5:7, 6:2, 6:14 called 5:9 came 58:1 can't 7:6, 14:14, 53:23, 65:6, 65:15, 76:15 canister 32:17, 33:2, 59:8, 59:10, 59:13, 59:14, 59:20, 59:21, 59:22, 59:25, 60:4, 60:6, 60:8, 60:20, 61:10, 61:11, 61:18, 66:7, 66:19, 66:21, 67:4, 69:14, 78:19, 79:14, 80:16, 80:18, 81:12, 81:19, 81:23, 81:24, 82:2, 82:5 canisters 32:18 cannula 72:15, 72:19, 73:2 capabilities 41:5 capital 54:8 caption 84:18 cardiac 25:17, 25:23,
---	--	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

88

29:8, 29:16, 29:18 cardiologist 55:24 cardiologists 55:21 cardiopulmonary 71:15, 71:18, 71:24, 71:25, 72:20, 73:4, 73:7 cardiothoracic 55:21 care 1:5, 5:14, 6:8 case 1:13, 1:16, 1:18, 5:17, 46:11, 54:17 cases 53:17, 53:19, 54:9, 54:10 catalog 79:24 categories 16:14, 17:5 catheter 10:24, 11:3, 11:9, 11:13, 11:14, 11:17, 11:22, 12:3, 12:4, 12:8, 12:11, 12:12, 12:13, 12:15, 12:18, 13:2, 20:9, 25:6, 30:16, 30:19, 31:9, 31:20, 32:3, 32:9, 32:12, 35:4, 35:5, 36:11, 36:13, 36:20, 37:7, 39:20, 40:1, 41:3, 41:8, 41:11, 41:16, 41:19, 42:2, 42:7, 42:10, 42:12,	42:15, 42:21, 42:24, 43:18, 43:22, 44:6, 44:11, 44:20, 49:1, 49:10, 49:11, 49:19, 49:24, 50:5, 50:6, 50:13, 50:15, 51:1, 56:18, 57:13, 57:23, 58:9, 58:11, 58:14, 59:12, 62:21, 73:11, 73:12, 73:15, 73:17, 73:21, 74:1, 74:6, 74:9, 76:22, 82:8, 82:10, 82:13, 82:14 catheterization 55:11 catheters 11:8, 11:16, 12:9, 18:7, 20:20, 21:9, 21:11, 41:5, 43:6, 73:10, 77:2 cause 19:22, 21:4, 22:20, 22:23, 23:17, 34:6, 34:25, 47:5, 51:7, 84:10, 84:18 caused 24:20 causing 26:24, 51:3 cava 29:5, 29:21, 50:10 cc 56:15, 56:23, 56:24, 57:3, 57:8 ccs 56:17, 56:19,	56:21 cedars-sinai 56:9 cells 46:24, 47:5 cellular 46:23 center 49:10, 50:7 centrifugal 21:10 century 2:15 cerebral 73:25 certain 12:9 certainly 15:14, 16:23, 18:3, 18:12, 19:9, 19:24, 20:1, 21:14, 23:6, 30:25, 32:2, 32:10, 33:24, 36:1, 36:8, 36:10, 38:18, 40:25, 41:18, 43:20, 47:4, 47:17, 51:9, 51:21, 57:8, 61:9, 61:12, 62:2, 69:12, 69:19, 74:25, 79:25 certificate 84:1 certified 5:6, 84:4 certify 84:5, 84:15 cetera 20:20, 41:22 chamber 32:16, 32:22, 33:5, 59:9, 60:7, 60:8, 60:12, 60:15, 61:3, 61:15,	61:21, 61:23, 62:1, 62:8, 62:10, 62:13, 62:16, 62:18, 62:22, 62:23, 63:8, 63:11 chambers 29:8, 29:16, 29:18, 30:17, 31:15 chance 19:11, 82:14 chances 27:9, 47:15, 52:8, 82:14 change 51:19, 52:8 changed 46:10, 51:25 changes 53:1 channel 49:11, 49:12 choices 51:18 choose 70:8 choosing 18:23, 70:9 chose 26:19 chosen 35:2 chronic 34:18, 37:16, 37:22 circulation 37:17, 37:23, 37:24, 72:2, 72:6 cite 38:11, 65:19 claims 21:22, 41:2 clarify 8:17, 18:18, 44:19, 64:2 clarity 3:24
--	---	--	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

89

clear 38:10 clinical 23:7, 23:8, 57:15 clinically 24:13, 24:16 clip 20:20, 38:20, 38:21 clog 82:10, 82:17 clogs 82:13, 82:14 close 35:16, 75:24, 76:2, 78:10 closed 60:17, 63:1 clot 13:12, 13:20, 19:17, 19:20, 36:23, 40:23, 46:20, 47:3, 47:10, 47:16, 47:24, 48:1, 48:6, 48:13, 48:21, 50:2, 50:19, 51:12, 52:4, 52:22, 61:1, 73:25, 74:5, 82:19 clots 19:1 clotting 49:3, 52:8 coagulability 52:3 coie 2:13, 6:6 collected 32:21, 53:9, 53:22, 54:4, 54:14, 55:1, 55:14, 58:1, 66:25, 67:3, 67:6, 68:19, 69:5, 69:10,	69:14, 82:5 collection 30:17, 31:15, 32:16, 32:18, 32:22, 33:2, 33:5, 66:19, 66:21 column 80:2 com 2:10, 2:19 come 26:21, 45:13 coming 65:23 commencing 5:3 commercial 32:19, 63:24, 64:3 commercially 67:12, 67:13, 67:15, 68:17 common 32:2 communicate 45:23, 71:2 comparable 21:14, 21:20, 22:11, 42:20, 43:13, 43:17, 44:17, 45:1 comparing 50:3, 80:5 comparison 79:9 complete 7:3, 7:7 completely 79:18 complication 19:11, 27:9, 27:11, 27:18, 27:19, 27:22 complications 18:13, 18:25, 19:4, 19:6, 19:8, 22:19,	22:22, 22:25, 23:5, 23:8, 23:12, 24:8, 24:11, 24:25, 25:11, 27:14 component 18:24, 25:20, 30:22, 31:4, 31:10, 31:21, 32:2, 32:12, 32:13, 32:23 components 25:25, 26:22, 30:11, 31:14, 31:22, 32:7, 32:8, 34:10, 34:11, 35:12, 51:6 compressive 42:4 concern 33:22 concluded 83:3 conditions 42:8 confirm 10:12, 33:25, 44:16 confusion 8:14, 9:4 connected 59:8, 62:17, 72:14 connector 62:25 connection 59:19, 59:21, 59:24, 59:25 connectors 69:20, 69:23, 69:24 consequence 52:23 consider 11:10, 15:16, 15:24, 18:9, 24:24, 25:3,	25:4, 25:12, 31:3, 34:4, 73:16 consideration 18:4, 18:16, 18:19, 19:20, 35:6, 37:2 considerations 13:1, 20:18, 20:23, 20:24, 36:5 considered 25:8, 26:3, 26:7, 26:9, 32:14, 33:1, 33:23, 52:16, 74:1, 74:6 considering 26:17, 34:2 consisted 19:21 constant 37:6 constantly 37:13 contact 18:23, 35:3, 49:20, 49:21, 49:25, 56:1 contacting 18:5, 18:6 contain 56:18 content 21:21 context 13:3, 13:13, 73:20, 78:20, 78:25 continuation 41:1, 41:2 continued 54:6 continuous 61:20 contraindications 28:13, 28:15, 28:19, 29:22
---	--	--	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

90

contribute 49:3, 50:2 contributes 42:17, 42:19, 44:22 control 49:4, 49:9, 49:12, 49:13, 49:14 controller 49:13 conversion 25:20 copyright 65:16 correct 8:20, 11:15, 12:6, 12:9, 12:13, 18:19, 30:3, 36:18, 37:4, 38:13, 38:14, 38:25, 39:2, 40:14, 41:17, 43:10, 43:11, 43:19, 44:2, 44:9, 44:23, 50:20, 57:7, 60:1, 60:9, 62:8, 62:24, 64:3, 67:18, 68:1, 70:4, 75:5, 76:9, 76:17, 81:20, 81:25, 82:17 could 9:10, 9:14, 24:21, 29:14, 29:16, 30:5, 31:24, 32:5, 32:14, 35:24, 37:11, 38:15, 42:11, 43:23, 43:25, 44:1, 44:5, 44:6, 44:9, 48:24, 52:2, 53:3, 56:11, 56:21,	56:25, 58:23, 69:20, 74:14, 79:25 couldn't 62:22, 62:25 counsel 6:3, 6:18, 39:7, 63:18, 63:22, 64:1, 84:15 county 56:8 couple 45:9, 63:5 court 6:10, 6:13, 6:17 covering 34:12 create 60:3, 60:21, 61:17, 61:23, 62:3, 62:10, 63:1, 72:21, 73:8 created 18:14, 59:14 creates 59:9, 62:12, 73:1 creating 63:11 critical 19:1 cross-sectional 77:21 csr 1:34, 6:14, 84:23 current 47:18 D date 5:18, 65:16 dated 84:20 days 54:16	declaration 8:1, 8:16, 8:19, 8:24, 8:25, 9:2, 9:11, 10:23, 19:13, 30:9, 33:14, 38:4, 39:10, 40:11, 40:18, 45:4, 46:14, 53:4, 58:24, 63:17, 63:21, 64:9, 64:16, 64:23, 65:17, 65:18, 66:3, 70:6, 71:10, 74:24, 75:2, 77:13, 79:17 declarations 8:15, 8:23, 10:15, 10:19 decrease 50:10 deep 30:4, 30:6 defect 25:16 definition 10:13, 10:18, 10:22, 11:2, 12:2, 12:19, 13:2, 14:9, 21:16 definitions 73:24, 81:7 deliver 25:23, 40:2, 41:16, 41:20, 42:8, 42:16, 42:25, 43:18, 44:1, 44:4, 44:12, 44:21 delivered 44:9, 60:25 delivery 24:4, 29:15, 35:19, 36:20, 40:1, 41:15, 41:19, 42:1,	42:6, 42:15, 42:24, 43:18, 44:11, 50:5 depending 82:18 depends 27:21, 30:13, 30:17, 30:24, 31:6, 32:10, 33:7, 61:4, 66:14, 67:2, 73:18, 73:20 deploy 35:14 depos 2:23, 5:22, 6:11 deposited 59:11 deposition 3:1, 5:2, 5:13, 5:25, 83:1, 84:6, 84:10, 84:17 depositions 7:9, 7:12 describe 13:24, 14:19, 14:21, 16:11 described 18:21, 38:23, 39:16, 59:7 describes 68:3 description 4:8, 14:25, 15:7, 45:1 design 10:24, 11:3, 11:13, 11:17, 11:22, 12:3, 12:8, 12:11, 12:12, 12:15, 12:18, 13:2, 17:20, 18:3, 19:9, 19:24, 20:18, 20:22, 20:24, 21:4,
--	--	--	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

91

26:24, 27:2, 35:10, 35:19, 35:22, 36:1, 36:5, 37:2, 41:5, 42:20, 42:21, 43:22, 48:16, 49:11, 51:21, 82:12, 82:15, 82:17 designed 18:15, 18:17, 18:18, 19:3, 19:16, 27:8, 66:17, 68:5, 69:4, 69:9, 69:13, 72:5 designing 11:14, 18:2, 19:8, 19:21, 22:18, 23:3, 24:10, 24:14, 24:18, 24:25, 25:9, 25:12, 26:17, 27:13, 27:17, 33:21, 36:6, 39:17 designs 42:9, 47:18 desirable 42:3, 82:9 detach 35:18 detailed 45:2 details 10:5 determine 73:20 determined 80:15 develop 17:12 developed 43:6, 44:20 developing 20:1, 21:7, 43:17, 43:20, 49:7	development 20:19, 27:15, 35:6, 35:13, 39:11, 44:14, 48:8, 54:8 device 18:2, 18:11, 19:5, 19:8, 19:14, 19:16, 19:21, 20:1, 20:5, 20:8, 20:16, 20:21, 20:22, 21:2, 21:4, 21:12, 22:18, 22:23, 23:3, 23:13, 24:10, 24:15, 24:18, 24:21, 25:1, 25:9, 25:12, 25:19, 26:11, 26:24, 27:2, 27:8, 27:13, 27:17, 28:19, 28:21, 28:23, 29:9, 30:18, 33:21, 33:25, 34:3, 34:5, 34:25, 35:2, 35:10, 35:12, 35:14, 35:15, 35:16, 35:17, 35:18, 35:24, 36:7, 39:17, 39:19, 40:22, 42:3, 44:2, 44:4, 44:21, 46:22, 47:12, 48:9, 48:16, 49:5, 49:8, 49:14, 49:17, 50:4, 51:1, 51:5, 51:11, 53:15, 78:22, 78:24, 79:4, 79:12, 80:1, 80:3, 80:5, 80:6, 82:13, 82:17	device's 19:22 devices 17:20, 18:5, 18:6, 18:15, 18:21, 18:22, 19:3, 19:9, 21:8, 21:10, 21:13, 25:22, 28:17, 32:19, 40:2, 41:16, 41:20, 41:22, 42:8, 42:11, 42:16, 42:25, 43:4, 43:8, 43:19, 44:8, 44:13, 44:14, 44:18, 52:13, 52:15, 52:17, 52:20, 54:18 diameter 26:7, 75:25, 76:3, 76:8, 76:11, 76:22, 76:23, 76:24, 77:22, 78:6 difference 10:9, 13:22, 14:1, 14:14, 15:19, 24:18 differences 9:24 different 8:4, 10:4, 10:6, 16:15, 21:8, 34:10, 34:14, 39:6, 41:6, 43:19, 50:4, 51:1, 57:5, 63:5, 80:7 differential 59:6, 61:21 differentiate 14:4 differently 14:19, 14:22 dilator 58:10	direct 3:25, 15:23, 34:11 directly 15:23, 24:14, 24:17 discharge 73:5, 73:8 disclose 40:22, 41:9 disclosed 42:7 discloses 42:15, 77:20 disclosure 52:25 disconnect 58:17 discuss 47:18, 74:12 discussed 4:12, 42:9, 50:18, 62:11 discusses 48:14, 48:15 discussing 14:11, 47:11, 47:25, 48:22 discussion 47:14, 47:22, 48:4, 48:11, 48:19 disinterested 84:13 dislodged 29:14, 29:17 dislodgement 25:21 disrupt 50:13 disrupted 51:17 disrupting 50:16, 51:3 dissection 26:12 distal 76:1, 76:10
--	--	--	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

92

disturb 51:6	36:25, 37:1, 45:24, 46:2,	embolic 41:9, 41:10,	essentially 62:7, 80:23
disturbing 52:24	49:4, 54:21,	41:24, 42:17,	estimate 76:12
divide 75:13, 75:21	66:4, 66:16,	43:23, 44:4	et 20:20, 41:22
doctor 29:9	66:25, 67:6,	embolism 19:20, 30:2,	europe 55:12
document 9:5, 9:7,	68:19, 69:5,	40:23	evacuate 66:7
23:24, 24:3,	69:10, 71:3,	embolisms 29:24, 74:10	evaluate 21:21, 22:13,
28:12, 37:25,	71:6, 72:1	embolization 25:20	43:15
40:6, 42:15,	dyspnea 24:20	emergency 25:22	evaluating 19:22
65:19, 77:1,	E	employed 42:11	evaluation 34:22
77:7, 79:7,	each 8:6, 8:10,	end 33:17, 34:8,	even 33:10, 35:4,
79:13, 81:4	8:18, 10:5	50:22, 71:12,	52:5, 76:23
documents 3:8, 7:22,	earlier 50:18, 58:9	83:1	events 24:9, 24:12,
7:23, 7:25, 8:6,	early 54:16, 54:21,	endovascular 41:21	24:25, 25:11
46:2, 64:15,	58:8	engine 78:18, 80:17,	ever 55:13, 57:21,
64:22, 71:6	easily 52:4	81:19, 81:22	57:23, 58:20,
doing 54:20	east 2:15	engineering 27:15, 34:9	64:12, 67:5,
done 15:14, 34:21	effect 18:10	engineers 11:8, 23:7	67:10
double-check 38:16	efficient 75:9	enough 21:21, 43:14,	every 19:2, 19:5
doubt 79:21	effusion 25:18	61:11	everyone 6:13
down 28:9, 33:17,	either 15:17, 35:1,	entire 38:18	evidence 29:4, 29:7
49:10, 56:8,	39:5, 82:24,	eptfe 49:23	ex-plants 38:22
77:16, 78:5,	84:16	equivalence 79:3, 81:1,	exact 10:2, 17:17
79:11	electric 31:25	81:3	exactly 17:18
dozens 22:25, 53:16,	elements 26:21	equivalent 77:22, 80:21	examination 4:3, 6:22
55:3, 55:4	else 51:7, 51:17,	erosion 25:18	examined 5:11
drainage 25:6	64:25	error 39:7	example 15:21, 25:9,
drive 5:23	emboli 18:14, 25:22,	especially 54:20	34:7, 36:13,
duly 5:10, 6:20,	46:20, 47:1,	esquire 2:5, 2:14	51:3, 63:19,
84:8	47:3, 47:7,		
during 20:19, 23:13,	47:9, 47:16,		
25:7, 29:17,	47:24, 48:6,		
32:1, 35:7,	48:13, 48:21		

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

93

70:7, 76:6 excuse 7:13, 8:16, 11:18, 17:7, 36:4, 45:4, 50:1, 60:6, 61:13, 80:17 exhibit 4:8, 8:7, 8:10, 23:23, 23:25, 28:12, 38:1, 38:7, 38:11, 38:12, 38:15, 39:4, 40:6, 40:8, 40:10, 40:22, 42:7, 44:12, 65:10, 65:11, 65:13, 65:20, 65:25, 74:16, 74:17, 74:19, 75:7, 77:8, 77:9, 77:15, 78:11, 78:13, 78:15, 78:21 exhibits 4:10 existing 69:24, 79:3 exists 51:1 expand 81:6 expel 72:18 experience 10:24, 11:3, 11:10, 11:14, 11:17, 11:20, 11:22, 12:3, 12:8, 12:11, 12:12, 12:15, 12:18, 13:2, 17:24, 20:12, 20:15, 21:3, 21:7, 21:15, 21:20, 22:12, 27:15, 42:19,	42:21, 43:10, 43:13, 43:17, 43:21, 44:17, 45:2, 52:14, 63:13, 64:7 experimented 34:9 expert 14:7, 14:12, 21:5, 21:18, 21:23, 22:7, 22:15, 27:5, 27:10, 27:19, 27:25, 28:3, 28:7, 42:18, 43:4, 43:14, 44:13 expertise 21:21, 22:12, 44:22 explains 60:24 exposed 47:20, 60:19 extensive 43:21 extent 20:11, 20:12, 20:14, 50:16 external 76:8 F fact 42:14, 44:20, 51:10, 75:2 failure 25:23, 25:24 fair 9:8, 19:19, 20:11, 20:14, 26:23, 27:17, 34:23, 35:8, 50:14, 51:2, 51:8, 61:24, 77:1 familiar 17:7, 38:22,	43:7 fda 78:16, 79:1, 80:8, 80:15, 80:21 fda's 80:25 feature 70:6, 80:11 feel 9:6 femoral 29:5, 29:8, 29:13, 29:18, 29:21, 30:5 fever 24:19 few 54:9 fibrillation 25:16, 28:6, 28:7 field 9:21, 9:25, 10:9, 13:3, 13:13, 14:7, 14:12, 16:21, 54:19 fields 42:20 figure 31:13, 59:2, 62:16, 62:24 filter 31:23, 33:11 filtered 58:20 filters 30:16, 31:16, 31:22 filtration 41:10, 41:25, 42:17 find 65:2 finish 52:2 finished 22:4, 33:3	finishes 35:3 firm 17:7 first 5:10, 6:20, 9:15, 26:15, 37:14, 75:2 fistula 25:16 five 33:17 flexible 42:3 floor 2:7, 6:1 flow 49:2, 49:4, 49:11, 49:12, 49:13, 49:14, 50:1, 50:5, 50:7, 50:8, 50:13, 50:14, 50:16, 51:3, 51:6, 51:7, 51:16, 51:20, 51:25, 52:13, 52:15, 52:20, 52:21, 52:24, 60:13, 75:9 flowing 49:16, 49:22 fluid 51:19, 51:24, 52:9, 52:15 flush 36:19, 37:6, 37:12 flushing 36:11 focusing 66:2 following 4:10 follows 5:11, 6:21 foregoing 84:6
---	---	--	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

94

form 17:15, 46:25, 47:1, 48:17, 50:19, 52:21 formation 16:22, 17:2, 17:6, 18:1, 18:9, 20:16, 33:22, 34:24, 35:1, 35:11, 35:23, 36:4, 36:17, 36:22, 46:19, 47:2, 47:15 formations 16:25 formed 18:14, 47:9, 47:24, 48:6, 48:12, 48:20 forming 47:12, 69:16, 70:3 forth 44:12, 52:25, 64:8 found 66:19 foundation 13:6, 13:18, 14:17 four 10:23, 11:3, 11:9, 12:2, 12:7, 12:10, 12:15, 12:18, 33:16 francisco 1:24, 5:5, 6:1 free 9:6, 37:9 french 73:13, 73:16, 74:1, 74:6, 74:9, 74:13, 75:12, 75:14, 75:15, 76:1, 76:2, 76:4,	76:6, 76:15, 76:18, 77:2, 77:5, 77:25, 78:1, 78:4, 78:8, 78:9 frequency 80:12, 80:15 frequently 32:17, 54:17 friday 84:20 full 7:3, 7:7 fully 68:5 function 63:10 further 11:21, 82:22, 84:15 G gathered 20:15 gave 15:21 general 11:9, 24:23, 52:12 generally 30:14, 47:7, 52:16, 55:20, 56:15, 61:25, 71:21, 71:23, 72:10, 73:11 generate 59:5 getting 50:7 give 7:6, 40:5, 69:2 given 16:24, 17:3, 17:5, 69:14, 73:14 gives 21:21 go 28:9, 30:7,	31:8, 33:11, 38:16, 48:3, 48:10, 61:3, 61:6, 61:8, 71:9, 77:16, 79:11 goal 23:6, 47:4 goes 61:2, 77:4 going 7:22, 8:14, 8:23, 9:7, 23:22, 29:9, 30:7, 37:25, 45:5, 45:14, 58:18, 65:9, 70:18, 71:11, 74:15, 77:7, 78:11, 83:2 good 6:13, 6:24, 50:17, 51:21, 70:14 google 65:1 graph 39:12 greater 77:21 guess 26:6, 26:9, 33:1, 61:10 guide 58:11 guidewire 50:6, 50:25 guiding 56:18, 57:13, 57:23, 58:9 H half 45:6, 76:7 hamilton 2:14, 4:3, 6:5, 6:23, 10:20, 11:12, 13:10,	13:21, 14:20, 17:23, 22:3, 22:14, 27:16, 27:23, 32:6, 41:13, 45:8, 45:19, 52:18, 64:21, 70:12, 70:16, 70:23, 72:9, 82:21 hamilton@ashurst- perkins 2:19 hand 7:22, 23:22, 37:25, 62:18, 65:9, 74:15, 77:7, 78:11 handing 40:6 happen 50:21 happens 82:19 happy 70:13 head 75:17 heading 79:8 headquartered 5:22 heart 15:22, 72:1 helping 54:17 helps 44:16 hematoma 25:25 hemolysis 25:25, 49:4, 49:16, 50:2, 50:11 heparinized 36:25, 37:6, 37:13, 52:6 here 5:12, 7:7,
---	--	--	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

95

7:12, 7:13, 10:8, 13:4, 13:14, 22:13, 38:8, 38:23, 41:9, 42:9, 49:19, 53:15, 57:2, 59:18, 60:10, 61:25, 63:5 hereby 84:5 high 42:4 higher 17:13 highly 42:3 hills 56:10 hospitals 57:5 hour 45:6, 46:6, 70:10 hourly 46:8 housing 65:3 human 53:17 humans 55:17 hundreds 53:16, 55:3, 55:4, 55:7 hungerford 5:23 hypertension 26:1 hypotension 26:1	identified 63:20 identify 25:10, 55:25, 56:12, 63:16, 63:21 ifu 23:1, 56:25 image 74:25 immediately 58:16 imperative 1:5, 5:14, 6:8 implant 34:13, 34:17 implanted 25:22 implanting 52:16 implants 18:8, 21:12, 38:21 imply 15:11 importance 32:5, 48:22 important 20:22 inari 1:8, 5:14 inc 1:5, 1:8, 5:14, 5:15 inch 75:8, 75:12, 75:15 inches 76:1, 76:14, 76:23 incision 26:2 include 20:4, 20:25, 29:23, 30:2, 30:4, 41:23, 63:16 included 47:19	includes 44:25 including 42:11, 42:12, 42:16 increase 52:7 increases 82:13 index 3:1 indicated 28:24 indication 28:17, 67:22, 68:1, 68:3 indigo 78:18 individual 11:1 industry 21:14, 21:20, 22:12, 42:21, 43:13, 43:17, 43:21, 44:17, 45:1 infarction 26:6 infection 25:5, 26:1, 26:2 inferior 29:4, 29:20, 50:10 information 65:25, 74:21 infrequently 82:19 infuse 58:18 injected 57:19 injury 26:4, 26:5 inlet 72:10, 72:14, 72:17, 72:21, 72:25, 73:2	inner 75:25, 76:22, 76:24 insert 29:9 inserted 58:10, 72:15 insertion 26:2 inside 36:12, 49:22, 57:12, 65:3, 76:3, 76:23 instance 24:19, 24:23, 30:20, 31:24, 32:1, 36:20, 42:12, 42:13, 67:16, 67:20, 68:18, 75:3 instead 39:21, 47:1 instructed 3:3 instructions 22:24, 23:14, 23:16, 24:5, 28:16 integrated 68:5 intended 23:8, 25:24 intent 61:9, 61:12, 61:16, 61:17, 61:22, 82:15 interested 84:17 interfere 50:13 internal 76:11 interventional 55:20, 55:24 intracardiac 29:4, 29:20 intravascular 53:8, 54:25
I			
id 75:8, 75:12, 75:16 idea 50:17			

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

invasive 41:21	joseph 2:14, 2:19, 6:5	79:7	led 39:11, 64:5
invention 41:19	joshua 2:5, 2:10, 6:7	labs 55:11	left 21:9
involve 30:19	journal 37:17, 37:24	laceration 26:13	leg 26:8
involved 21:22, 38:18, 51:19	july 1:23, 5:2, 5:18, 84:20	lack 13:5, 13:17, 14:16	less 52:21, 56:17, 56:19, 56:21, 57:8, 76:11, 78:1
involving 58:6	K	52:19	lesser 57:6
ipr 1:13, 1:16, 1:18, 4:12, 4:14, 5:17, 23:23, 38:1, 40:7, 74:16	k 78:17, 79:1, 80:8, 81:4	laminar 52:15, 52:19, 52:21	let's 26:15, 49:23, 61:17, 63:4, 71:9, 80:11, 81:8
irvine 2:8	k-a-r 56:6	lane 1:22, 5:8, 5:13, 6:19, 83:1, 84:7	license 6:14
ischemia 26:6	kar 56:6, 56:7	language 80:22	likelihood 19:25, 49:15
iso 34:21	keeping 37:8	large 50:9, 52:12, 73:21, 73:23, 74:2, 74:7, 75:8, 77:17, 77:20	likely 17:14, 50:19, 51:15, 52:21
issue 7:12, 13:4, 13:14, 17:19, 17:20, 22:13, 30:15, 35:9, 36:16	key 18:24	larger 73:11, 74:4, 74:8, 74:11, 76:15	limit 11:18, 12:8
issues 47:18	kind 15:8, 44:5	largest 76:4	limitations 12:14, 12:17
italic 46:17	kink-resistant 42:3	last 19:13, 28:25, 31:8, 31:20, 41:23, 48:7, 48:25, 53:25, 54:2	limits 12:25
item 41:24	knobbe 2:4, 5:3, 6:7	later 57:20	line 3:4, 3:9, 3:14, 3:19, 33:17, 77:16, 78:5
items 32:3, 41:23	know 9:5, 14:14, 25:4, 30:9, 40:19, 53:4, 56:20, 59:2, 65:4, 66:11, 71:13, 74:3, 79:22, 79:23	lead 47:20, 48:1, 48:24	liner 49:23
iterated 19:24	knowledge 18:25	leaflet 26:11	lines 33:17, 37:10, 78:5
iterations 34:8, 79:19	known 26:19	leaflets 35:15, 35:18	list 21:8, 24:8, 24:11, 26:16, 29:25, 34:8, 35:19, 44:8, 44:10, 75:25, 76:1
itself 32:3, 49:10, 50:5, 50:6	L	learned 55:22	listed 23:1, 29:22,
ivc 29:8	label 59:18		
J	labeled 24:7, 59:16, 59:18, 60:7, 60:10, 79:5,		
job 1:35			

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

97

38:5, 38:7, 38:14, 39:1, 39:3, 41:6, 76:4, 76:21 lists 24:19, 76:23 llp 2:4, 2:13 located 56:7 location 36:24, 51:15, 73:18 lock 35:17 long 35:19, 36:24, 44:8, 44:10, 58:13, 58:16, 76:21, 77:6, 81:4 long-term 18:8 longer 60:19 look 8:6, 9:10, 10:5, 10:11, 10:21, 14:3, 17:25, 19:12, 23:16, 24:7, 26:20, 28:25, 37:14, 38:6, 39:9, 39:22, 47:13, 48:25, 49:6, 56:25, 59:17, 62:6, 71:9, 81:8 looking 9:8, 46:13, 65:17 looks 24:5, 74:25 los 2:17 lot 16:5 low 61:11	lumen 44:5, 50:6, 50:9, 50:25, 56:17, 77:18, 77:21, 78:6 lumens 36:11, 36:13, 36:20, 37:7, 37:9, 37:11 lunch 70:13, 70:20 M made 19:24, 69:1 magazine 37:24 main 2:6 make 27:18, 27:25, 35:24, 43:9, 44:13 makes 21:5, 43:3, 43:14 malposition 25:19 maneuvers 82:20 many 20:18, 20:22, 21:8, 23:1, 23:10, 23:12, 23:15, 23:18, 24:13, 24:21, 31:1, 44:21, 53:7, 54:22, 54:23, 54:24, 55:2, 67:14 march 78:17 marked 3:18, 8:7, 23:23, 40:6, 65:9, 74:16, 77:8, 78:11 marks 3:24, 82:25	martens 2:4, 5:4, 6:8 maryland 5:23 mass 50:8 massive 29:15 material 18:2, 43:24, 44:4, 48:15, 48:23, 50:8, 50:11, 51:18, 51:24, 61:1 materials 17:11, 17:14, 18:23, 26:19, 34:12, 35:2, 35:3, 47:19 math 75:17 matter 5:14, 8:20, 45:25, 46:5, 69:17 matters 7:10, 7:13, 8:18, 69:18, 70:4, 71:3 max 65:2, 66:2, 66:12, 66:17, 66:25, 67:7, 69:3, 69:8, 69:11, 74:21, 74:22, 75:5, 79:14, 79:15, 80:16, 81:12, 81:24, 82:2 maybe 31:16, 32:13, 51:7, 74:13 mean 11:14, 12:11, 13:4, 13:16, 14:23, 15:8, 16:16, 17:10, 24:16, 27:10,	28:15, 28:21, 28:22, 29:3, 32:16, 37:20, 41:1, 41:15, 42:6, 46:19, 46:24, 47:2, 49:18, 52:20, 53:13, 78:24, 80:20, 81:16 means 13:19, 14:25, 15:1, 15:9, 29:5, 59:19, 59:20, 66:20, 78:22, 81:14 meant 11:20 mechanic 67:23 mechanical 13:15, 13:22, 14:15, 14:24, 14:25, 15:3, 15:9, 15:10, 15:12, 15:16, 15:19, 15:24, 16:1, 16:2, 16:5, 16:7, 22:16, 30:12, 30:22, 31:5, 32:8, 32:23, 33:6, 44:23, 68:4, 68:6, 68:9, 68:19, 69:5, 69:10 mechanics 51:19, 51:24, 52:9 mechanisms 37:10 medela 63:10, 63:14, 63:16, 63:25, 65:3, 65:19, 65:24 media 5:12 medical 1:8, 5:15,
--	--	---	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

98

17:20, 18:2, 18:10, 19:5, 28:17, 31:2, 53:8, 54:25 medications 7:2, 17:4 medicines 17:5 meet 14:9 meeting 11:1 meets 12:1, 33:25, 34:3, 80:25 mention 21:14 mentioned 29:18, 31:22, 41:23, 41:24 metal 26:22, 34:10, 34:11 micro 35:17 microcatheter 76:23, 77:4 might 7:2, 15:24, 17:11, 26:21, 53:24, 56:25, 66:15 migration 25:18 minimally 41:21 minimize 19:10, 19:25, 23:7, 26:24, 27:14, 27:18, 34:13, 36:14, 53:1 minimizing 20:21, 35:6, 35:10, 36:2, 36:3 minutes 45:10	misstates 31:17, 52:10 mistake 38:15, 39:5 mistakenly 39:7 mitigate 23:5 mitraclip 19:14, 19:16, 19:21, 20:5, 20:8, 20:16, 20:19, 21:2, 21:4, 21:12, 22:18, 22:23, 23:3, 23:13, 24:4, 24:10, 25:1, 25:9, 25:12, 25:18, 25:19, 25:20, 25:23, 25:24, 26:17, 29:11, 33:21, 34:3, 34:9, 34:24, 35:10, 35:14, 36:6, 37:16, 53:15, 53:18, 53:19, 53:25, 58:7 mitral 20:9, 26:4, 26:5, 26:14, 35:15 modifications 19:25 monitor 5:19 more 12:14, 14:25, 15:6, 15:8, 17:12, 17:14, 24:21, 24:22, 34:21, 34:22, 45:9, 49:7, 50:19, 51:15, 52:4, 52:15, 52:19, 52:21, 73:12, 79:24	morning 6:13, 6:24 most 49:21, 54:10, 74:9 mostly 53:15, 53:18 move 61:14 much 6:17, 56:14, 66:15, 67:3, 74:11 multiple 19:5, 50:25, 52:2, 52:4 myocardial 26:5 myself 67:19, 68:11, 68:16 N name 6:14, 38:5, 79:18 named 84:11, 84:18 necessarily 3:25, 24:14, 24:17, 24:20, 44:13, 50:24, 66:9 necessary 33:5 need 31:25, 43:10, 45:9, 63:1, 79:2 needed 37:5, 37:12 negative 18:10, 59:6, 72:21, 72:22, 72:24, 73:1 neglected 21:13 nested 41:7	new 80:6 next 39:22, 58:12, 75:24, 81:8 nickel 26:21 non-sterile 81:17, 81:23, 82:3 non-thrombogenic 35:21, 35:25 none 3:5, 3:10, 3:15, 3:20 noon 70:13 normal 27:14, 52:24 notation 75:8 note 3:23 nothing 84:9 notice 5:1, 75:24, 78:16 notification 79:2 novel 39:12 number 8:3, 8:5, 8:7, 8:10, 18:21, 41:6, 41:10, 49:9, 75:21, 76:25 numbers 5:17, 79:24 numerous 50:4, 53:14 O oath 6:25, 45:21, 70:25 objection 10:16, 11:6,
--	--	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

99

13:5, 13:17, 14:16, 17:21, 22:1, 22:9, 27:12, 27:20, 31:17, 40:24, 52:10, 64:18, 72:4 observe 54:2 observed 53:7, 53:13, 53:20, 54:12, 54:24, 57:24, 67:19 occlusion 26:12 occur 55:10, 58:5 occurred 55:8, 58:12 od 76:1, 76:10, 77:5, 77:6 office 1:1, 5:16 okay 40:21, 45:12, 53:6, 59:4, 71:14 olson 2:4, 5:4 once 61:2 one 8:3, 8:5, 8:10, 10:3, 10:5, 20:22, 22:19, 23:18, 26:15, 32:15, 35:20, 37:21, 38:6, 40:13, 41:3, 41:8, 43:16, 48:4, 52:7, 54:2, 56:5, 58:8, 62:12, 63:6, 65:6, 65:7, 76:20, 76:21, 77:8,	79:22, 82:12 ones 25:3, 25:14, 74:3 only 65:19, 76:20 onset 46:10 open 15:14, 35:16, 39:21, 62:25, 72:1 opened 15:22, 60:24 operate 63:7, 64:17, 64:19, 71:22, 80:23 operates 62:1, 62:7 operating 61:20 opinion 9:16, 11:5, 11:25 opinions 69:17, 70:4 opposite 82:16 options 70:8 orange 56:8 order 15:22, 19:25, 34:12, 62:4, 63:11, 72:23 ordering 74:20 ordinary 9:17, 10:14, 11:4, 11:11, 12:1, 12:5, 12:19, 17:25, 21:16, 82:3 other 11:1, 12:1, 12:17, 15:12,	15:13, 16:1, 16:3, 16:7, 16:8, 16:14, 17:4, 19:4, 19:8, 21:13, 22:22, 26:21, 31:13, 31:21, 34:2, 34:4, 35:23, 36:3, 36:5, 38:17, 40:2, 41:4, 41:11, 41:16, 41:20, 42:8, 42:10, 42:16, 43:10, 44:8, 44:12, 44:14, 44:22, 51:6, 53:19, 56:23, 57:14, 57:16, 59:24, 59:25, 63:20, 64:15, 65:24, 79:19, 79:22, 82:19 others 16:11, 16:12, 16:13, 23:2, 31:16, 32:14, 56:11, 56:12 out 26:22, 31:13, 49:9, 51:13, 58:14, 61:14, 65:2 outcome 84:17 outlet 62:15, 62:17, 62:22 outlined 23:14 outside 35:5, 49:2, 49:12, 49:14, 49:25 over 18:22, 55:11 overfilled 61:10	own 52:3 owner 1:9, 2:12, 5:9, 6:6, 21:15 oxygenator 72:7 P pacific 5:20 page 3:4, 3:9, 3:14, 3:19, 4:2, 4:8, 9:14, 18:20, 24:7, 28:11, 30:8, 33:15, 33:16, 39:10, 39:24, 46:14, 46:15, 58:23, 58:25, 59:1, 59:2, 59:5, 60:23, 61:25, 62:7, 62:12, 63:6, 66:3, 68:3, 71:12, 71:16, 75:1, 75:7, 75:25, 76:5, 76:7, 76:19, 77:15, 79:5, 79:6, 81:5 pages 1:36 paragraph 9:14, 9:15, 10:22, 12:23, 14:10, 18:20, 19:12, 21:17, 30:7, 31:9, 33:13, 33:15, 33:16, 34:7, 37:14, 38:3, 38:10, 39:9, 39:16, 39:22, 39:24, 40:10, 40:16, 40:17, 40:18, 41:6, 42:1, 42:23,
---	---	---	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

100

45:3, 47:13, 47:22, 48:2, 48:4, 48:10, 48:11, 48:18, 48:19, 49:1, 50:22, 53:1, 53:3, 58:23, 59:1, 65:18, 71:9, 71:10, 71:12, 74:23, 77:12, 79:16 park 2:15 part 19:2, 27:14, 38:16, 41:2, 52:25 partially 40:17 particular 80:10 particularly 41:21 parties 84:16 partly 37:8 partnership 55:23 past 18:18 patent 1:1, 1:3, 1:9, 1:14, 1:17, 1:19, 2:12, 5:9, 5:15, 5:16, 6:6, 7:15, 7:16, 8:2, 8:4, 8:5, 9:22, 10:11, 16:4, 21:15, 38:9, 47:17, 49:6, 59:17, 62:19, 64:3 patents 7:11, 7:18, 7:20, 10:1, 10:10, 13:3, 13:7, 13:14,	13:15, 14:4, 14:8, 14:13, 14:18, 14:21, 16:11, 16:22, 21:22, 22:13, 30:15, 43:15, 74:12 path 49:2, 49:14, 50:1, 50:5, 50:7, 50:8, 50:13, 50:14, 50:16, 51:22, 52:13 patient 13:9, 13:20, 13:25, 15:2, 15:7, 15:18, 16:19, 17:2, 18:13, 19:11, 23:7, 29:10, 31:24, 32:21, 33:12, 47:7, 51:13, 57:10, 57:19, 58:10, 58:15, 60:5, 60:11, 61:2, 66:4, 66:10, 66:12, 66:13, 66:18, 66:21, 66:22, 68:21, 69:2, 69:15, 69:22, 72:8, 72:16, 73:3, 82:4 patient's 52:3, 53:9, 53:21, 54:4, 54:14, 55:1, 55:14, 57:25 patients 15:15, 16:24, 17:3, 17:5, 20:3, 20:8, 28:23, 29:6, 29:7, 33:9, 36:24, 52:5 patterns 52:24	pdt 1:26, 1:30, 5:3 penumbra 63:10, 63:25, 64:5, 65:2, 66:2, 66:12, 66:17, 66:24, 67:7, 68:4, 68:20, 69:3, 69:8, 69:11, 74:21, 74:22, 75:5, 78:16, 78:18, 79:14, 79:15, 80:16, 80:17, 81:12, 81:19, 81:22, 81:24, 82:2 perforation 25:17, 26:13 perform 20:5, 20:7, 21:1, 39:17, 44:21, 57:21, 62:5, 63:11, 66:7, 67:17, 71:25 performed 26:20, 32:11, 33:25, 55:23, 67:11, 82:20 performing 20:25, 25:7, 26:3 pericardial 25:18 peripheral 26:6 perkins 2:13, 6:6 permanent 18:8 permanently 35:17 person 9:17, 10:14, 11:4, 11:11, 11:25, 12:5, 12:19, 17:24,	21:16, 64:13, 70:7, 82:3, 84:13 personal 63:13, 64:7 personally 5:7, 67:8 petitioner 1:6, 2:3, 6:8 petitioner's 8:2 pharmaceuticals 16:23 philip 2:22, 5:21 photos 51:11 phrase 46:17, 47:8, 53:7, 71:15 physically 54:13 physician 20:20, 30:25, 33:7, 54:13, 54:19, 58:13, 61:4, 62:4, 66:14, 66:22, 66:24, 67:2, 67:5, 68:23, 68:25, 69:4, 69:9, 69:20 physicians 16:14, 53:8, 53:21, 54:3, 54:25, 55:18, 55:19, 55:25, 56:5 pigs 55:16 piston 65:8 place 5:25, 84:11 planet 2:23, 5:22, 6:11 play 20:19
--	---	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

101

please 6:3, 9:6, 11:19 plus 21:12 point 9:4, 28:25, 29:1, 39:24, 45:7, 46:15, 56:8 pons 63:10, 63:25, 64:2, 64:3, 68:3 poorly 46:25 port 58:18, 61:10, 72:11, 72:14, 72:17, 72:21, 72:25, 73:2, 73:5 portions 49:18, 49:24, 50:12 positive 73:8 possible 45:11, 61:11, 70:1 potential 17:13, 18:25, 19:4, 19:5, 19:22, 21:4, 22:19, 22:25, 23:12, 23:17, 24:8, 24:11, 24:24, 25:10, 34:5, 41:7, 41:11, 46:24, 48:15, 51:10 potentially 24:12, 30:16 pre-market 79:2 predicate 78:21, 78:24, 79:8, 79:12, 80:3, 80:5 preparing 54:18	present 2:21, 29:6, 29:7, 41:19, 54:13, 55:7 presentation 51:11 pressure 59:6, 61:21, 72:21, 72:22, 72:24, 73:1, 73:8 presume 67:12 presuming 67:14 pretty 43:21, 75:24, 78:10 prevent 7:3, 16:24, 17:1, 17:6, 17:25, 19:7, 23:4, 27:9, 36:12, 36:17, 37:3, 47:5 preventing 16:22, 34:24, 36:3, 46:19, 47:11, 47:15, 48:8 prevention 20:16, 47:25, 48:14 prevents 46:22 previously 23:23, 25:22, 74:16 previously-marked 4:10 primarily 37:8 primary 30:11, 30:21, 31:4, 31:10, 31:14, 31:20, 32:5, 32:7, 32:12, 32:13,	33:22, 33:24, 35:9, 35:13 principle 62:8, 63:7 prior 34:8, 41:24, 46:13, 51:5, 51:10, 54:11, 68:4 probably 17:4, 22:25, 38:20, 38:21, 69:19, 76:13, 78:4 procedure 23:13, 24:22, 25:6, 25:7, 25:8, 26:10, 29:17, 30:17, 32:4, 36:25, 37:1, 43:7, 53:16, 54:20, 55:22, 58:3, 58:4, 58:6, 58:8, 62:5, 66:8, 66:16, 67:3, 67:8, 67:10, 82:9 procedures 15:15, 21:11, 31:2, 32:1, 42:22, 44:18, 44:22, 53:8, 53:14, 53:24, 54:3, 54:25, 55:23, 57:24, 57:25 proceed 6:18 proceeding 58:12 proceedings 83:3 proctor 54:20 production 3:8 products 18:4	project 19:2, 49:7 projects 18:24 prolonged 26:8 prone 17:12 pronounce 33:19 proposed 10:13, 10:21, 14:10, 21:15 protocols 38:19 provide 12:14, 63:22, 69:21, 70:6, 72:22, 79:24 provided 33:9, 38:7, 38:8, 39:6, 57:10, 63:18, 64:1, 72:24, 81:17 provides 21:14, 22:12 providing 33:12 publication 47:17 publications 38:17 published 37:16, 37:23 pull 37:10, 72:23 pulmonary 29:23, 30:2, 74:5, 74:10 pulse 60:25 pulsing 60:21 pump 21:10, 31:25, 59:5, 59:7, 59:9, 59:15,
---	---	--	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

102

59:20, 59:21, 60:18, 61:13, 61:14, 61:19, 61:22, 61:25, 62:6, 62:11, 62:20, 63:6, 63:14, 63:16, 64:3, 64:5, 65:2, 65:3, 65:7, 65:8, 65:19, 65:24, 66:2, 66:3, 66:6, 66:9, 66:12, 66:17, 66:19, 66:25, 67:7, 67:9, 67:11, 67:13, 67:23, 68:9, 68:20, 69:3, 69:6, 69:8, 69:11, 70:9, 71:19, 71:24, 71:25, 72:2, 72:6, 72:20, 72:23, 73:4, 73:7, 73:8, 74:21, 74:22, 75:5, 78:18, 79:11, 79:14, 79:15, 80:12, 80:16, 80:17, 81:12, 81:19, 81:23, 81:24, 82:2 pumps 30:16, 31:15, 31:24, 62:10, 63:5, 63:9, 63:20, 63:22, 63:24, 64:8, 64:10, 64:11, 64:16, 71:16, 71:22, 72:5, 72:10, 72:13 purely 32:11 purpose 44:2	pursuant 5:1 put 12:25, 49:11 putting 25:6 Q qualification 11:22 qualifications 9:17, 42:18 qualified 43:3, 43:10 qualifies 12:5 qualify 11:3 question 14:4, 17:22, 23:21, 28:10, 30:8, 30:10, 31:7, 39:23, 40:20, 48:10, 48:18, 51:4, 53:2, 53:5, 62:14, 65:5, 68:14, 69:7, 71:11, 71:13 questions 3:3, 3:18, 47:14, 48:3, 59:2, 59:3, 82:22, 82:23 quite 38:22, 43:7 quotation 3:24 quote 3:25, 9:16, 34:11 quoted 40:17 quotes 60:8 R range 11:7, 73:23,	74:13 rate 46:8, 46:10 re-ask 17:22 reaction 25:15, 26:16, 26:18, 26:25, 27:3 reactions 27:6, 27:24, 28:1 read 17:17, 21:25, 22:6, 22:24, 65:15 ready 30:10, 40:19, 53:5, 59:3, 71:13 real 34:16 really 34:17, 50:24, 55:4 reason 7:6, 57:14, 57:15, 57:16, 79:21 reasonable 76:2 reasonably 26:10 receive 72:17 receives 72:19 recently 65:1 reception 59:8, 59:10, 59:13, 59:14, 60:6, 60:8, 61:18 recess 45:16, 70:20 recite 37:15	recognize 7:23, 24:3, 40:8, 65:11, 74:17, 77:9, 78:13 reconnect 58:17 record 45:15, 45:18, 70:19, 70:22, 83:2 recovery 24:22 reduce 27:9, 49:2 reducing 46:21, 46:23, 47:2, 47:15, 49:3, 49:15, 50:2 refer 7:19, 8:14, 8:22, 8:23, 43:16 reference 19:13, 38:2, 38:9, 39:6, 39:7, 39:11, 40:1, 49:19, 77:11, 77:17 referenced 38:19, 40:10, 74:23, 79:16 referred 77:11 referring 7:19, 9:2, 9:5, 9:20, 54:10 refers 13:8, 17:11 reflect 3:25 regarding 8:2, 45:24, 71:3, 78:17 regardless 12:3, 12:12 regulations 79:1, 81:5
--	---	---	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

103

regurgitation 20:9, 26:14 reinforced 75:9, 75:16 reinfuse 66:8, 66:9, 66:22, 66:24, 69:4, 69:9 reinfused 53:9, 53:21, 54:3, 54:14, 55:1, 55:13, 56:14, 57:7, 58:15, 58:21, 66:12, 66:18 reinfusing 67:6 reintroduce 82:4 relate 36:21, 39:17, 47:8, 47:14, 47:23, 48:5, 48:11, 48:19, 50:23 related 18:25, 20:12, 24:13, 24:14, 24:16, 24:17, 24:21, 24:22, 25:5, 25:7, 33:22, 34:25, 35:23, 36:5, 41:2, 41:9, 41:24, 42:21 relates 8:4, 8:5, 26:7, 44:17, 48:7 relating 36:10, 50:24 releases 47:6 rely 65:24 remained 50:19 remember 53:23, 64:4,	65:6, 78:9 remembered 5:1 removal 13:8, 41:10, 41:25, 42:17, 47:23, 48:5, 48:12, 48:20 remove 15:1, 15:15, 15:22, 15:25, 19:16, 35:16, 44:4, 66:20, 69:13, 69:20 removed 58:11, 66:16 removing 13:20, 13:24, 15:7, 15:18, 16:15, 16:16, 16:18, 43:23, 47:8, 50:16, 50:25, 51:20 repeat 69:7 rephrase 20:13, 51:4 reply 8:2 reported 1:32, 84:13 reporter 5:6, 6:10, 6:13, 6:17, 84:1, 84:5 reporter's 3:23 reports 38:20 represent 6:4 representing 5:22, 6:11 request 3:8 required 32:22 requirement 34:21	requirements 11:2, 12:2, 13:1, 34:1, 35:20, 35:22, 36:1, 36:8, 36:10, 80:25, 81:2, 81:6 respect 26:17, 34:5, 35:9, 36:6, 65:18, 80:10 result 18:12, 23:9, 37:22 results 37:16, 37:23 retrieve 25:24 return 66:4, 72:7, 72:14 returned 68:20 returning 31:23 review 46:2, 71:6, 78:17 rid 50:7 right 9:22, 15:4, 15:9, 18:16, 19:23, 22:20, 23:11, 28:1, 29:19, 51:21, 52:1, 52:9, 73:22, 75:8, 75:18, 75:20, 75:23, 76:13, 76:16, 80:18, 82:16, 82:21, 82:25 risk 50:10 rockville 5:23 room 54:13, 55:7	rotating 60:14, 60:16, 60:17, 60:21 rough 62:18 row 81:8 rpr 1:33, 84:23 ryan 1:33, 5:5, 6:11, 6:14, 84:4, 84:23 S s-a-i-b-a-l 56:6 saibal 56:6, 56:7 said 11:17, 12:7, 12:21, 18:15, 18:17, 21:25, 22:6, 22:19, 23:10, 24:2, 27:24, 31:15, 32:15, 34:3, 38:17, 43:12, 51:23, 53:18, 54:24, 55:3, 64:2, 84:10, 84:12, 84:16, 84:18 saline 37:6, 37:13 same 8:3, 10:2, 10:13, 10:17, 10:18, 14:23, 22:17, 28:11, 33:13, 42:23, 47:13, 48:2, 48:10, 48:18, 62:7, 63:3, 63:7, 66:8, 73:14, 74:22, 74:25, 79:18, 79:22, 79:25,
--	--	---	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

104

80:7, 80:16, 80:19, 80:20, 80:23, 81:20 san 1:24, 5:4, 6:1 saw 54:9 say 11:13, 11:20, 12:10, 16:20, 17:14, 17:15, 19:19, 20:11, 20:14, 26:23, 27:17, 32:5, 34:23, 35:8, 37:8, 41:4, 41:14, 43:25, 46:25, 49:23, 51:2, 52:19, 54:12, 55:5, 55:18, 58:16, 60:23, 61:17, 61:24, 75:21, 77:1, 80:10, 80:11 saying 42:1, 75:8 says 10:23, 29:4, 31:9, 31:20, 41:18, 42:23, 44:1, 46:21, 48:7, 60:23, 68:3, 76:10, 80:19, 81:13, 81:20 scope 10:7 scrubbed 54:17, 55:4, 55:6 sealed 59:22, 60:1, 60:2, 62:1, 62:2, 62:8, 62:13, 63:7 search 65:1	second 8:3, 8:19, 48:3, 76:5, 79:6, 80:2 section 21:8, 45:2 see 8:8, 8:12, 9:15, 10:5, 10:23, 14:4, 19:13, 23:24, 28:12, 29:1, 31:11, 37:18, 39:14, 40:1, 40:3, 43:1, 46:14, 46:17, 53:7, 53:11, 59:17, 62:18, 63:4, 65:21, 71:15, 75:7, 76:6, 76:25, 77:17, 77:23, 78:6, 79:8, 80:2, 80:13, 81:10 seem 64:4, 78:9 seemed 51:21 seems 75:24, 76:1 seen 51:11, 64:12 select 76:22 sense 69:1 sentence 9:15, 19:13, 31:8, 31:19, 31:20, 37:15, 41:18, 41:25, 43:5, 43:9, 44:3, 48:7, 48:25, 50:22, 54:24 septal 25:16	set 44:11, 52:25, 64:8, 65:15 several 7:9, 70:8 shape 35:2 shapes 34:10 sheath 26:8, 76:20, 76:21, 77:5 sheaths 77:6 short 26:10 short-term 18:7 shorthand 5:6, 84:4 should 28:18, 28:19, 28:22, 29:10, 35:20, 39:3, 46:25, 50:10 show 34:19, 63:9, 70:7, 76:22, 79:2 showing 51:11, 62:17 shown 21:17, 59:5, 61:25, 62:6, 63:24, 76:18, 81:5 shows 77:2 side 18:10, 54:8 signature-plkal 84:21 significant 62:3, 69:1, 70:6 significantly 10:6 similar 50:3	similarly 63:10 simple 44:6 since 46:10 single 26:11, 44:5 sit 10:8, 57:2 site 25:24, 26:2, 48:15, 51:9 six 33:17 sixth 33:17 size 50:9, 73:13, 73:16, 74:9, 75:12, 75:14, 75:15, 76:4, 76:21, 77:2, 82:18 sizes 74:12 sketch 62:18 skill 9:17, 10:14, 11:4, 11:11, 12:1, 12:5, 12:19, 17:25, 21:16, 70:7, 82:3 skilled 82:12 slightly 10:4 small 36:12, 73:17, 73:21, 73:23, 74:2, 74:7 smaller 73:12, 74:4, 76:24 smallest 76:18, 76:24
--	---	--	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

105

smooth 46:22 smoothness 35:5 some 15:8, 21:13, 38:17, 50:16, 55:21, 57:6, 59:1, 74:12 something 49:8, 51:7, 51:17, 58:5, 76:2, 78:1 somewhere 56:9 soon 45:11 sorry 22:4, 29:6, 34:18, 41:1, 41:24, 45:3, 50:6 sound 75:23 sounds 75:20 source 32:13 spasm 26:13 speaking 73:11 specific 14:25, 15:4, 15:6, 15:8, 28:18, 49:7, 64:11 specifically 68:6 specification 10:3, 10:4 specifics 79:24 specify 11:16, 57:1 st 6:1 staff 54:18	stagnant 36:24, 50:19, 50:23 stagnating 36:12 stagnation 36:21, 37:4 standard 25:21, 32:4 standpoint 26:10 start 26:15, 36:9 state 5:6, 6:4, 18:20, 43:22, 81:18, 81:22 statement 50:14, 68:8 states 1:1, 5:15 stating 38:11 steerable 41:3, 41:5, 42:10, 43:20, 44:7 steering 41:8 stem 47:18 stenographic 84:1 stenographically 1:32, 84:12 stenosis 26:5 stent 39:12 stentriever 30:18, 30:20, 42:13 step 57:20, 58:12 steps 17:1, 19:7, 19:9, 58:9 sterile 54:19, 81:13,	82:7 sterilization 26:3, 81:9 still 15:24, 37:1, 37:11, 45:21, 54:9, 70:25 stipulations 3:13 stop 70:14 stopcocks 31:1, 32:4 stopping 45:6, 70:15 stowell 2:5, 6:7, 10:16, 11:6, 13:5, 13:17, 14:16, 17:21, 22:1, 22:9, 27:12, 27:20, 31:17, 40:24, 45:5, 52:10, 64:18, 70:10, 72:4, 82:23 stowell@knobbe 2:10 street 2:6, 5:4, 6:1 strength 42:5 stroke 26:11 studies 20:2, 34:17, 34:18, 34:19 study 37:16, 37:22, 38:18, 38:23, 38:24, 39:1 sub 24:6 subject 71:3, 80:3 submitted 8:19 subscript 24:6	subset 15:3, 16:5 substance 45:24 substantial 79:3, 80:25, 81:3 substantially 80:21 suction 42:12 sufficient 11:10, 22:12 suite 2:16, 5:23 summary 61:24 supplemental 8:1, 8:24, 8:25, 9:12, 9:13, 10:18, 10:22, 30:9, 33:14, 38:3, 39:10, 40:11, 40:18, 45:4, 46:14, 53:4, 58:24, 63:21, 64:8, 64:9, 65:18, 71:10, 74:23, 77:12, 79:16 supplied 64:15, 64:22 support 3:1, 8:2 sure 14:3, 14:18, 15:16, 16:10, 16:13, 17:18, 25:4, 35:24, 38:5, 43:5, 51:18, 56:2, 56:16, 56:20, 56:22, 56:24, 57:2, 57:4, 57:18, 64:6, 66:20, 73:1, 79:19, 79:20,
--	--	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

106

79:25 surface 17:12, 17:15, 18:1, 35:3, 46:22, 52:2 surgeon 15:16, 15:21 surgeons 15:14, 55:21 surgery 25:21, 25:23, 39:21, 72:1 surgical 15:17, 15:20, 16:1, 16:2, 16:7, 41:22 sworn 5:10, 6:12, 6:16, 6:20, 84:8 syringe 31:25, 33:1, 53:10, 53:22, 54:5, 54:15, 55:2, 55:15, 56:15, 56:23, 56:24, 57:3, 57:6, 57:8, 58:1, 58:17, 69:14, 69:21 syringes 30:16, 31:15, 32:3, 57:5 system 20:10, 20:19, 24:4, 25:20, 25:25, 29:11, 29:15, 30:12, 30:13, 30:19, 30:22, 30:24, 31:4, 31:6, 31:10, 31:14, 31:21, 32:8, 32:23, 33:6, 33:7, 35:19, 36:14, 36:15, 37:13, 39:20, 41:3, 41:8, 41:12, 41:15,	42:10, 43:21, 44:7, 63:1, 68:5, 70:2, 74:6, 78:18 systems 30:14, 31:1, 32:18, 32:20, 33:8, 33:10 T take 9:10, 19:7, 23:4, 24:7, 45:12, 70:17, 72:6, 72:13, 80:11 taken 51:13, 84:11 taking 5:2, 5:25, 17:1 talk 16:4 tamponade 25:17 team 23:7, 34:9 technical 9:21, 9:25, 10:9, 13:13, 14:7 telescoped 41:4, 41:7 tell 6:20, 75:20, 84:8 telling 14:13 temporary 18:6 tend 32:19 tensile 42:4 term 13:15, 15:10, 16:14, 16:20, 17:1, 17:8, 17:10, 32:17,	32:19, 33:18, 33:19, 54:22 termed 17:16, 17:18, 47:7 terms 14:2, 14:5, 14:23, 16:15, 30:2, 30:3, 32:15, 73:12, 80:6 test 33:24, 34:4, 34:16, 34:22 tested 20:2 testified 5:11, 6:21 testify 5:10 testimony 1:21, 7:3, 7:7, 31:18, 44:24, 44:25, 52:11, 84:12 testing 26:20, 34:20 th 2:7 thank 6:17, 9:13, 78:5, 82:21 themselves 6:4 thereafter 84:14 thereby 46:23, 49:15 therein 84:11 thereof 5:3 thermodilution 21:9 thing 14:23 things 25:5, 43:16,	51:23, 52:2, 52:5, 52:7 think 11:9, 13:19, 13:24, 14:24, 15:6, 16:5, 22:11, 23:15, 30:13, 30:24, 31:6, 31:19, 33:10, 39:5, 42:19, 43:12, 44:16, 44:25, 50:21, 51:9, 52:12, 52:23, 53:20, 53:23, 54:9, 55:3, 56:25, 61:16, 63:18, 63:24, 66:14, 67:2, 68:13, 69:19, 70:5, 74:3, 74:8, 74:12, 76:6 thinking 52:13, 53:15 third 8:5, 10:3, 80:2 thornton 1:22, 5:8, 5:13, 6:19, 6:24, 45:20, 70:24, 83:1, 84:7 thought 39:8, 50:17 thoughts 10:12 three 7:22, 7:23, 8:15, 8:22, 10:10, 10:14, 10:15, 10:18, 29:22, 30:2, 30:3 thrombectomy 13:4, 13:8, 13:15, 13:23, 14:15, 14:24,
--	--	---	---

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

107

15:3, 15:4, 15:5, 15:12, 15:13, 15:17, 15:20, 15:23, 15:24, 16:2, 16:3, 16:6, 16:9, 16:18, 20:6, 20:7, 20:12, 20:25, 21:1, 21:6, 21:19, 21:24, 22:8, 22:16, 30:12, 30:14, 30:15, 30:23, 31:5, 32:1, 32:9, 32:11, 32:24, 32:25, 33:6, 39:18, 42:18, 43:23, 44:6, 44:18, 44:21, 44:23, 57:22, 58:2, 58:3, 62:5, 63:12, 66:5, 66:8, 67:1, 67:7, 67:17, 67:21, 67:24, 68:4, 68:6, 68:10, 68:19, 69:6, 69:10, 82:9 thrombo 23:17 thromboemboli 19:1 thromboembolic 50:11 thromboembolism 19:23, 21:5, 22:20, 23:18, 47:21, 48:1, 48:24, 49:15 thrombogenic 47:19, 48:15, 48:23 thrombogenicity 17:8, 17:13, 33:18, 34:1,	34:4, 34:15, 34:16, 34:20, 36:2 thrombosis 20:21, 25:19, 30:4, 30:5, 30:6 thrombus 13:8, 13:11, 13:25, 15:1, 15:7, 15:15, 15:18, 15:25, 16:15, 16:17, 16:19, 16:22, 16:24, 17:2, 17:6, 17:12, 17:15, 18:1, 18:10, 18:14, 19:1, 19:17, 19:20, 20:1, 20:17, 29:5, 29:7, 29:13, 29:15, 29:16, 29:20, 29:21, 33:23, 34:6, 34:13, 34:19, 34:25, 35:1, 35:7, 35:11, 35:23, 36:4, 36:6, 36:14, 36:17, 36:22, 40:23, 46:20, 47:3, 47:4, 47:6, 47:9, 47:11, 47:16, 47:24, 48:6, 48:8, 48:12, 48:20, 51:10, 51:16, 52:21 through 33:11, 35:11, 36:11, 36:19, 37:6, 37:13, 42:10, 44:7, 45:2, 45:3, 49:16, 49:22, 60:13, 60:14, 60:25, 61:6, 61:8, 72:7	thrush 40:25 thrust 41:1 tia 26:12 time 5:19, 26:11, 36:24, 46:5, 56:9, 58:17, 67:13, 70:15, 82:22, 84:11 times 67:14 titled 80:3 today 5:21, 6:10, 7:4, 7:7, 7:12, 7:13, 10:8 today's 5:18 took 19:9, 24:9, 58:17 tool 15:25 top 46:15, 71:11, 71:16 torsional 42:4 toward 34:7 tract 25:5 trademark 1:1, 5:16 trained 55:22 transcribed 84:14 trauma 26:12 treat 20:8, 27:2, 39:12, 39:19, 42:8, 74:9	treated 29:10 treating 27:5, 27:10, 27:19, 27:25, 28:4, 28:7, 47:9, 73:25, 74:5 treatment 40:23, 47:23, 48:5, 48:12, 48:20 trial 1:3, 5:16 troy 1:22, 5:8, 5:13, 6:19, 83:1, 84:7 truth 5:11, 6:21, 84:8, 84:9 truthful 7:3, 7:7 try 82:17 trying 29:14, 31:13 tube 59:16, 60:14, 60:18, 61:1, 61:6, 61:8 tubing 60:13, 75:9, 75:16 turbulent 51:7 turn 9:14, 28:11, 33:13, 40:16, 48:2, 53:3, 58:23, 77:15, 79:5 turned 60:18, 61:19 two 10:2, 10:23, 11:2, 11:9, 12:2, 12:7,
--	--	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

12:10, 12:15, 12:18, 14:1, 14:5, 51:23, 78:5 two-part 41:3, 41:8, 41:11, 41:14, 42:9, 43:20, 44:7 type 12:4, 12:12, 13:1, 15:4, 30:18, 32:10, 32:18, 65:2, 65:7, 65:8 types 11:16, 12:9, 15:13, 16:3, 16:8, 31:1, 31:2, 40:2, 41:20, 43:15, 43:19, 44:12, 44:14, 71:21 typewriting 84:14 typically 57:9, 74:8	updated 80:6 urinary 25:5 use 10:2, 16:15, 18:7, 20:2, 20:21, 22:24, 23:14, 24:5, 31:7, 31:23, 31:25, 32:19, 35:7, 35:11, 35:24, 47:19, 49:4, 57:5, 62:4, 67:23, 68:9, 74:8 uses 41:11, 41:14, 65:2 using 14:25, 15:6, 15:8, 15:25, 20:5, 20:9, 30:18, 30:25, 32:25, 33:8, 62:9, 62:10, 66:12, 68:20, 69:6, 69:11, 82:8 usually 17:11, 55:23	62:10, 62:12, 62:13, 62:15, 62:20, 62:21, 62:22, 62:23, 63:2, 63:7, 63:11, 65:2, 65:7, 70:9, 72:22, 73:14 vague 10:16, 11:6, 17:21, 27:12, 27:20, 40:24, 64:18, 72:4 validation 26:4 valve 20:9, 25:21, 26:4, 26:5, 31:3, 31:7, 60:14, 60:16, 60:17, 60:21, 60:24 valves 30:21, 30:25, 31:16 variable 65:7 various 42:8 vascular 26:12 vasculature 74:1 vein 29:8, 29:13, 29:19, 29:21, 30:4, 30:6, 65:7 vena 29:5, 29:20, 50:10 venous 29:5, 30:5, 72:6, 72:15, 72:19 ventilation 26:9 ventricular 21:9	venture 54:8 versus 5:14, 24:17 vessel 15:22, 26:13 via 59:16 video 5:19, 5:25 videographer 2:22, 5:12, 5:21, 6:10, 45:14, 45:17, 70:18, 70:21, 82:25 videotaped 5:13 vision 15:23 voice-identify 6:3
U	V		W
uncovered 34:10 under 6:25, 45:21, 70:25 understand 6:25, 7:11, 7:18, 9:1, 9:7, 45:20, 70:24, 71:18, 71:21, 78:21, 81:14 understanding 14:22, 30:1, 65:23, 66:6, 66:23, 69:16, 70:3, 75:11 united 1:1, 5:15 universal 65:15	vacuum 32:13, 44:5, 59:7, 59:9, 59:14, 59:15, 59:20, 60:3, 60:7, 60:8, 60:12, 60:15, 60:18, 60:19, 60:22, 60:25, 61:3, 61:13, 61:14, 61:15, 61:17, 61:19, 61:21, 61:23, 62:1, 62:3, 62:8, 62:9,	ventilation 26:9 ventricular 21:9	want 39:23, 40:5, 40:16, 63:3, 66:15, 70:11, 70:12, 75:17 wanted 37:3, 37:5, 66:22 wanting 26:10 wants 61:4, 62:4 way 15:17, 26:3, 45:23, 71:2, 79:22, 80:24, 84:17 we're 9:6, 9:7, 14:10, 47:25 we've 7:9 wednesday 1:23, 5:2

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

109

welcome 6:24 went 26:8 weren't 62:2 whatever 57:6 whenever 45:6, 70:14 whereupon 6:16 whether 18:5, 18:7, 31:7, 34:2, 34:25, 55:6, 73:21 whole 6:20, 35:19, 84:8 wide 11:7, 73:23, 74:13 wires 49:10, 49:13, 50:4, 50:15, 50:25, 51:5, 51:12, 51:17, 51:20, 51:24, 52:1, 52:3 wish 54:3 withdraw 23:20, 28:9, 51:4, 53:1, 62:13 withdrawn 33:9 within 37:10, 41:4, 60:3, 60:19, 61:17, 77:4 within-entitled 84:10 witness 5:9, 6:9, 6:12, 6:16, 10:17, 11:7, 13:7,	13:19, 14:18, 17:22, 22:11, 27:13, 27:21, 31:19, 40:25, 52:12, 64:19, 70:14, 72:5, 84:5, 84:12 witnessed 67:8, 68:11, 68:16, 68:22 words 17:17 work 20:4, 20:15, 34:23, 37:11, 39:11, 39:16, 53:25, 54:6 worked 11:8, 18:4, 18:21, 19:2, 21:13, 54:6 working 36:14, 54:7 works 65:24 world 28:16, 43:22, 55:12 worsening 26:14 wouldn't 60:3, 62:3, 82:15 wraps 42:1 wrinkle 48:17 written 44:3, 46:25 wrong 38:8 Y yeah 16:13, 18:20, 45:11, 46:21, 63:24, 66:6, 70:14, 70:16,	77:5, 78:9, 78:10, 79:23, 80:8 years 10:24, 11:3, 11:9, 12:3, 12:7, 12:10, 12:16, 12:18, 18:22, 54:21, 79:19 \$ \$500 46:9 . .01312 75:13, 75:22 .025 76:24 .030 77:22 .04 76:22 .040 78:6 .0404 2:9 .088 75:11, 75:15, 75:25, 76:14, 76:21 .9900 2:18 0 0.088 75:8 01021 1:13, 4:14, 5:17 01025 1:16, 4:14, 5:17, 23:23, 38:1, 40:7, 74:16 01264 1:18, 4:12,	5:17 039 78:10 1 1 1:30, 1:36 10 19:12, 45:15, 45:18 1020 4:12, 77:8, 77:9, 77:16 1038 4:12, 78:12, 78:13, 78:15, 78:21 1039 4:12, 65:10, 65:11, 65:13, 65:20, 65:25 1067 4:12, 4:14, 8:11 1068 4:14, 74:16, 74:17, 74:19, 75:3, 75:7 1075 4:16, 23:23, 23:25, 28:12 1078 4:16, 38:1, 38:7, 38:11, 38:12, 38:15, 39:4 1079 4:16, 40:7, 40:8, 40:22, 42:7, 44:12 10993 34:21 11 1:30, 33:13, 33:15, 33:16, 70:19, 83:2 11,969,333 1:14, 8:3
---	---	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

CONFIDENTIAL - ATTORNEYS' EYES ONLY

Transcript of Troy Lane Thornton

Conducted on July 1, 2026

110

11,974,910 1:17, 8:5 11373 1:34, 6:15, 84:23 12 34:7, 48:2, 48:4, 70:22 12,016,580 1:19, 8:4 13 37:14, 38:3, 38:10, 83:2 14 2:7, 39:9, 39:16, 46:22, 71:12, 71:16 15 39:22, 40:11, 40:18, 58:23, 58:25, 59:1, 59:2, 59:5, 61:25, 62:12 16 1:26, 5:3, 5:19, 47:13, 47:22, 62:7, 62:12 17 48:10 1700 2:16 18 45:3, 48:18, 48:19, 50:23, 53:1, 60:23 1888 2:15 19 62:16, 62:24, 63:6 1st 5:18 2 2.3 77:25 2.4 78:4	2.5 78:4 2.6 77:5, 78:1 2012 54:1, 54:6, 54:10, 54:11 2013 24:5 2015 54:9 2018 78:17 2025 1:13, 1:16, 1:18, 4:12, 4:14, 5:17, 23:23, 38:1, 40:7, 74:16 2026 1:23, 5:3, 5:18, 84:20 2040 2:6 20850 5:24 21 6:1, 66:3, 75:1 22 68:3, 74:13 245 40:16, 41:6, 41:18 25 77:16 28 78:5 29 71:10, 71:12 3 30 56:19, 56:21, 57:4 31 77:12 310.788 2:18	32 58:23, 59:1 333 5:4, 6:1, 7:15, 7:19, 8:16, 8:24, 9:21, 9:25, 10:10, 13:14, 14:7, 14:12, 16:21 38 74:23, 79:16 4 40 65:18 400 5:23 43 70:22 45 45:15 451 5:22 5 502 62:20 510 78:17, 79:1, 80:8, 81:4 53 53:3 54 24:8, 28:11 57 45:18, 70:19 580 7:15, 7:19, 8:15, 8:23, 9:21, 9:25, 10:3, 10:6, 10:10, 10:11, 13:14, 14:8, 14:13, 16:21 6 6.7 75:23	60 56:15, 56:17, 56:23, 56:24, 57:3, 57:4, 57:8 638725 1:35 7 705 59:16, 59:18, 59:25, 61:6, 61:8 706 59:25, 60:14 707 59:8, 59:10, 59:22, 60:1, 60:6, 60:20, 61:3, 61:15, 61:21 708 60:13, 60:19, 61:1 711 60:14, 60:16, 60:17, 60:21 714 61:13, 61:19 721 47:18 8 84 1:36 9 9 1:26, 5:3, 5:19 90067 2:17 910 7:16, 7:20, 8:25, 9:10, 9:21, 9:25, 10:10, 10:22, 13:14, 14:7, 14:13, 16:21, 30:8, 33:14,
--	--	---	--

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

INARI-2018

Imperative Care Inc. v. Inari Medical, Inc., IPR2025-01025

38:3, 39:10,
40:11, 40:18,
45:4, 46:14,
53:4, 58:24,
64:9, 65:17,
71:10, 74:23,
77:12, 79:16

92614

2:8

949.760

2:9